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Cardiovascular disease is of public health significance due to its highest rates of mortality. 
Atherosclerotic cardiovascular events can often result in fatal or disabling non-fatal events. More 
than half of CHD fatal events do not show earlier symptoms. Early identification of subclinical 
atherosclerosis and establishment of preventive control are important to reduce CHD mortality 
and morbidity.  
The present study aimed to examine: 1) whether n-6 fatty acids are inversely associated 
with plasminogen activator inhibitor-1 (PAI-1) and fibrinogen; 2) whether vitamin D deficiency 
is associated with subclinical atherosclerosis; and 3) whether Japanese men have lower incidence 
or progression of CAC than Caucasian men, and further if marine n-3 fatty acids are inversely 
associated with incidence or progression of CAC. To test these aims, the Electron-Beam 
Tomography, Risk Factor Assessment among Japanese and U.S. Men in Post-World War II 
Birth Cohort (ERA-JUMP) study was utilized. 
The findings were: 1) in a population-based cross-sectional-sample of 915 men aged 40-
49, serum n-6 fatty acids were inversely and significantly associated with PAI-1 but not with 
fibrinogen; 2) in 295 middle-aged men of a population-based cross-sectional sample, Japanese 
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men showed lower levels of serum vitamin D, despite their habitual fish intake as a major dietary 
intake, than Caucasian or Japanese-American men. Further, vitamin D deficiency was not 
associated with subclinical atherosclerosis as measured by intima-media thickness (IMT) and 
CAC, except for significant associations on IMT in an univariate model among Caucasian men, 
and on CAC in both univariate and multivariate models among Japanese-American men; and 3) 
in the follow-up study of 472 men, Japanese men had a significantly lower incidence and 
progression of CAC than Caucasian men. Japanese men showed significant risk reduction on 
incident CAC associated with marine n-3 PUFA. However, Japanese and Caucasian men showed 
no significant associations of marine n-3 PUFA on the progression of CAC. Future studies to 
examine the causal associations as well as underlying mechanisms are warranted. From the 
public health importance, these findings extend our understanding of n-3 and n-6 
polyunsaturated fatty acids and vitamin D related to subclinical atherosclerosis as well as help to 
establish public health guidelines.  
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1.0  INTRODUCTION 
1.1 SPECIFIC AIMS 
Cardiovascular disease, the highest mortality worldwide
1
, occurs in different geographic patterns 
of distribution. Coronary heart disease (CHD) is more prevalent in Western countries, including 
the United States, whereas stroke is more prevalent in Asian countries.
2, 3
 Japan has a lower CHD 
mortality than Western countries.
4
 Although Japan have a high smoking prevalence, high levels 
of blood pressure, and similar serum total cholesterol levels, among the post-World War II birth 
cohort due to Westernized lifestyle, the CHD mortality rate in Japanese men is still very low; 
scientists refer to this low CHD mortality in the Japanese as „Japanese Paradox‟.2 Identification 
on the determinants of different geographical patterns for CHD risks across Western and Asian 
countries may help establish preventive strategies for reducing CHD morbidity and mortality. 
The present study will evaluate the associations of serum n-3 and n-6 fatty acids with subclinical 
atherosclerosis, as measured by carotid intima-media thickness (IMT) and coronary artery 
calcification (CAC), among three populations (Japanese men, Caucasian men, and Japanese-
American men) in the Electron-Beam Tomography, Risk Factor Assessment among Japanese 
and U.S. Men in Post-World War II Birth Cohort (ERA-JUMP) study.  
This ERA-JUMP study was initiated to examine the different prevalence rates of 
subclinical cardiovascular disease in multi-study sites. The baseline survey (from 2002 to 2006) 
 2 
was extended by the follow-up survey (from 2007 to 2012). From 2002 to 2006, men ages 40-49 
were randomly selected from four study sites (Otsu, Shiga, Japan; Pittsburgh, Pennsylvania; 
Honolulu, Hawaii; and Ansan, South Korea) within a population-based cross-sectional study. 
Some major findings of the ERA-JUMP study have shown that Japanese men have a lower 
prevalence of subclinical atherosclerosis measured by IMT and CAC than Caucasian men.
5
 Also, 
serum n-3 fatty acids have strong inverse associations with the prevalence of IMT and CAC.
6
 
The extremely low prevalence of subclinical atherosclerosis in the Japanese men has been 
shown, despite the similar or even higher risk factors for cardiovascular disease from their higher 
prevalence of smoking and higher alcohol consumption, as compared to Caucasian men.
6
 
Independent of traditional cardiovascular risk factors, the very low prevalence of subclinical 
atherosclerosis can be explained by their habitual intake of marine n-3 fatty acids, which may 
suggest anti-atherogenic effect.
6
 By comparing three study populations of Japanese, Caucasian, 
and Japanese American men from multi-study centers, the current study, which controls for 
genetic differences, assesses the environmental risk factors. 
 The present study has the following three specific aims and associated hypotheses: 
Specific aim 1: To examine the association of serum n-6 polyunsaturated fatty acids 
(PUFA), including linoleic (18:3n6, LA) and arachidonic (20:4n6, AA) acids with plasma PAI-1. 
Hypothesis 1. We hypothesized that higher serum n-6 fatty acids, including LA and AA, 
are associated with lower levels of PAI-1 in the ERA-JUMP cohort. 
Specific aim 2: To examine if serum vitamin D level in the Japanese men in Japan is 
higher, due to habitual fish intake as a major dietary source of vitamin D, than in the other two 
study populations of the Caucasian men and the Japanese American men; and to explore whether 
vitamin D deficiency (defined by 25(OH)D<20 ng/mL) is associated with subclinical 
 3 
atherosclerosis measured by IMT and CAC in a population-based cross-sectional sample of 295 
participants.  
Hypothesis 2. We hypothesized that the Japanese men in Japan showed higher serum 
25(OH)D level than the men in the other two study populations, Caucasian and Japanese 
Americans. We also hypothesized that IMT and CAC are associated with vitamin D deficiency, 
defined as serum 25(OH)D<20ng/mL in 295 men aged 40 to 49. 
Specific aim 3: To examine whether the incidence or progression of CAC is lower in the 
Japanese man in Japan than in the Caucasian men in the U.S.; and to examine whether marine n-
3 fatty acids are inversely associated with the incidence or progression of CAC.  
Hypothesis 3. We hypothesized that Japanese men in Japan have a lower incidence and 
progression of CAC, as compared to the Caucasian men in the U.S. We additionally 
hypothesized that higher marine n-3 fatty acids at baseline are associated with at lower risk for 
developing or progressing CAC in the ERA-JUMP follow-up study of 495 men. 
1.2 BACKGROUND 
1.2.1 Epidemiology of cardiovascular disease (CVD) 
According to the World Health Organization (WHO) in 2004, cardiovascular disease (CVD) is 
the leading cause of mortality throughout the world.
1, 7-9
 CVD occurs in different geographical 
patterns between Western and Asian countries. Western countries experience higher coronary 
heart disease (CHD) mortality, whereas Asian countries have more deaths from stroke than 
CHD.
2, 3
 For example, according to a recent update reported in the Circulation (2009)
10
, CHD 
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deaths between the U.S. (2005) and Japan (2004) for men ages 35 to 74 were 169.4 and 50.4 (per 
100,000 population) respectively.  
Atherosclerotic cardiovascular events can often be fatal or disabling nonfatal.
10
 The early 
identification of the presence or progression of subclinical atherosclerosis can result in a more 
effective prevention and target treatment. In the Cardiovascular Health Study (CHS), 38.7% of 
men and 36% of women among 5,201 participants ages ≥65 showed subclinical atherosclerosis.11  
1.2.2 Subclinical atherosclerosis 
Atherosclerosis is a progressive condition in which a fatty build-up accumulates and hardens, 
resulting in the narrowing or blocking of blood vessels. This fatty build-up grows and progresses 
into a plaque embedded in the artery walls. As the plaque enlarges, the artery walls expand to 
have the same amount of blood flow. When the elastic layers cannot stretch any more, the 
subsequent plaque rupture may occur depending on the lipid size as well as the thin fibrous cap. 
A larger lipid core or more vulnerable fibrous cap makes a plaque rupture more likely; a heart 
attack or stroke often results. This process may involve inflammatory and hemostatic responses.    
Researchers agree that an injury to the inner artery walls in the atherosclerotic 
progression initiates an inflammatory response.
12
 The injury attracts macrophage white blood 
cells and may also lead to blood clots.
12
 In response to the damaged site, monocytes traveling in 
the blood stream convert into macrophages by such oxidized cholesterol as LDL.
12
 Once 
macrophages eat and digest cholesterol molecules, they transform into a foam cell or plaque.
12
 
The artery wall injury usually leads to thrombotic and fibrinolytic responses on the 
endothelium.
12
 As macrophage-derived foam cells progress, they secrete pro-inflammatory 
cytokines.
13
 Simultaneously, smooth muscle cells within the arterial wall start proliferating. 
 5 
In the next section, two non-invasive methods (i.e., IMT and CAC) are reviewed as 
measurements of subclinical atherosclerosis.  
1.2.2.1  Carotid intima-media thickness (IMT)  
Carotid intima-media thickness (IMT), as measured by ultrasound technique, is a highly reliable, 
sensitive, and non-invasive measurement to identify the presence or severity of subclinical 
atherosclerosis, by measuring the first two layers of the carotid artery, even in an early stage.
14-16
 
Many large epidemiological studies, including a systemic review and meta-analysis review that 
combined eight other studies by Lorenz and colleagues,
14
 utilized IMT to quantify 
atherosclerotic burden and demonstrated strong associations with cardiovascular disease. As 
compared to the Framingham Risk Score, IMT has demonstrated a significant improvement to 
the prediction of CHD risk.
17
  
 
Table 1. Associations between intima-media thickness (IMT) and cardiovascular disease 
Author, year,  
study name  
Study population Follow
-up (yr) 
Exposure 
variable 
Outcome and results 
Hodis et al. 
(1998)
18 
CLAS 
146 men with previous 
coronary artery (40-59 
years) 
2 0.03mm IMT 
increase per 
year  
Nonfatal MI or coronary death,  
RR=2.2 (95% CI, 1.4-3.6)  
Any coronary event,  3.1 ( 2.1-4.5) 
O‟Leary 
(1999)
19 
CHS 
 
Longitudinal,  
5,858 participants aged 
≥65 without a history of 
CVD 
6.2  IMT Incident MI or stroke,  
RR= 3.87 (2.72-5.51) (highest 
quintile vs. lowest, with age and sex 
were adjusted) 
Chambless LE, 
et al. (1997)
20 
ARIC 
 
Longitudinal,  
12,841 aged 45-64 
without CHD at baseline 
5.2 
 
IMT 
(≥1mm vs. 
<1mm) 
Predictor of CHD incidence 
Hazard rate ratio (HRR)                
   =5.07 (3.08-8.36) for women 
HRR=1.85 (1.28-2.69) for men 
Chambless LE, 
et al. (2000)
21 
ARIC 
 
14,214 aged 45-64  7.2 IMT 
(≥1mm vs. 
<0.6mm) 
Predictor of ischemic stroke 
incidence  
HRR=8.5 (3.5-20.7) for women 
HRR=3.6 (1.5-9.2) for men 
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Table 1 (Continued).  
Author, year,  
study name  
Study population Follow
-up (yr) 
Exposure 
variable 
Outcome and results 
Mikkila et al. 
(2009)
22 
Young Finns 
 
A prospective 
cohort, 785 
subjects   
21  Long-term 
scores of a 
traditional 
dietary 
pattern 
IMT- in multivariate analyses 
for men (p<0.01),  
for women (p=0.66) 
Lorenz MW, et al. 
(2006) 
CAPS 
Longitudinal, 
Among 5,056 aged 
19-90 years) 
4.2 IMT at all 
carotid 
segments 
Per 1 SD IMT increase  
HRR=1.43 (1.35-1.51) for MI 
HRR=1.47 (1.35-1.60) for stroke 
HRR=1.45 (1.38-1.52) for all MI, 
stroke or death  
Salonen JT, et al. 
(1993)
23 
KIHD 
 
Longitudinal,  
1,257 men  
3 IMT For each 0.1mm of IMT, AMI risk 
increases by 11% (95% 6%-16%) 
Hazard ratio=2.1(0.8-5.2) for AMI 
Bots ML, et al. 
(1997)
24 
Rotterdam Study 
Nested case 
control, ≥55 years, 
Case-193 (98 MI, 
95 stroke) Control-
1,373 
2.7 IMT (Adjusted for age and sex) 
For stroke per 1SD increase 
(0.163mm) OR=1.41(1.25-1.82) 
For MI, OR=1.43(1.16-1.78) 
van der Meer  et al. 
(2004)
25 
Rotterdam Study 
6,389 participants, 
>55 years  
7-10 IMT 
 
For MI, Hazard ratio=2.91 (1.80-
4.70) (severe vs. no atherosclerosis 
based on the quartile of composite 
scores) 
Johnson HM, et al. 
(2007)
26 
Bogalusa Heart 
Study 
336 young adults 
(25-37years) in 
rural community 
5.8  
 
Progression 
of IMT  
CIMT progression rates in men 
(0.020±0.027mm/year) 
Smoking as an independent 
predictor (p=0.03) 
Kitamura A, et 
al.(2004)
27 
Yao city 
1,289 Japanese 
men ages60-74 
years 
4.5 IMT  
(quartile) 
For stroke, RR=3.0 (1.1-8.3)  
(IMT≥1.07 vs. ≤0.77mm) 
Murakami S, et al. 
(2005)
28 
LILAC study 
 
298 Japanese men 
and women 
ages≥75 years 
4.3 IMT  For all cause mortality, per 0.3mm 
increase in left IMT, RR=1.65 
(1.08-2.52), in right IMT, RR=3.33 
(1.43-7.75) 
For cardiovascular mortality, per 
0.3mm increase in left IMT, 
RR=2.35(1.03-5.37), in right IMT, 
RR=2.89 (1.06-7.89) 
ARIC, Atherosclerosis Risk in Communities Study; MESA, Multi-Ethnic Study of Atherosclerosis; CAPS, Carotid 
Atherosclerosis Progression Study; CHS, Cardiovascular Heart Study; CLAS, Cholesterol Lowering Atherosclerosis 
Study; KIHD, Kuopio Ischemic Heart Disease Risk Factor Study; LILAC study, Longitudinal Investigation for the 
Longevity and Aging in Hokkaido County study  
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1.2.2.2 Coronary artery calcification (CAC) 
Both Electron Beam Computed Tomography (EBCT) and Multi-Detector Computed 
Tomography (MDCT) are non-invasive and reliable measurements to identify the presence or 
progression of subclinical atherosclerosis.
29
 
30, 31
 Because the first manifestations of CHD events 
in asymptomatic individuals are often fatal without any previous symptoms, early identification 
of atherosclerosis is imperative.
4
  
Coronary artery calcification (CAC), as measured by either EBCT or MDCT, has 
demonstrated strong associations with cardiovascular events.
32
 A study in a general population 
ages 45-84 years without clinical cardiovascular disease showed a dose-response increase in 
risks of coronary events, according to the CAC scores of 1-100, 101-300, and >300 (Hazard 
ratios (HR) 3.9[1.7-8.8], 7.1[3.01-16.5], and 6.8[2.9-16.0], as compared to a zero CAC).
32
  
Previous studies showed that CAC improves CHD risk assessment, specifically for those 
in the intermediate category, based on a Framingham risk assessment using seven traditional 
cardiovascular risk factors (age, gender, smoking, total cholesterol, HDL, blood glucose, and 
blood pressure).
32, 33
 No racial/ethnic differences were observed in this improvement of the CHD 
risk assessment (Caucasian, Chinese, African-American, and Hispanic individuals).
32
  
However, several limitations on CAC make difficult in adopting into a routine screening 
practice: radiation exposure, lack of insurance coverage, and lack of risk stratification on clinical 
implication. 
With regards to controlling LDL cholesterol as a major fundamental risk factor, lipid-
lowering treatments (i.e., statins) have been examined to determine whether statins can hold off 
atherosclerotic progression. Several earlier trials found the effectiveness of statins on 
atherosclerotic progression,
34, 35
 but more recent trials did not show the effectiveness.
36-40
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Table 2. Coronary artery calcification (CAC) on Cardiovascular disease 
Study 
name  
Author, year Study population Follow
-up(yr) 
Exposure 
variable 
Outcome and results 
MESA Wang L., et 
al. (2006)
41
 
A cross-sectional 
study, 222 men and 
women ages 45-84 
without diagnosis of 
CHD, in the 
Minnesota field of the 
MESA cohort 
 Coronary artery 
calcification 
(CAC) 
Myocardial perfusion, Odds Ratio 
(95% CI) of CAC  
0             : 1 (reference) 
0.1-99.9  : 2.16 (0.96-4.84) 
100-399  : 2.81 (1.04-7.58) 
≥400       : 4.99 (1.73-14.4) 
Berry JD, et 
al. (2009)
42
 
2,988 participants ages 
≤50 years in the 
follow-up Year 15th 
CARDIA study, 1076 
participants ages ≤50 
years from MESA 
 As compared to 
low 10-year and 
low lifetime 
risk, those with 
a high lifetime 
risk and low 10-
year CVD risk 
In CARDIA, CAC progression 
OR(95%CI) 1.60 (1.15-2.24) for 
men 
1.68 (1.09-2.59) for women 
In MESA, CAC progression 
OR(95%CI) 
1.78 (0.99-3.22) for men 
1.52 (0.78-2.97) for women 
Kestenbaum 
BR., et al. 
(2009)
43
 
562 chronic kidney 
disease patients 
(mostly stage 3) 
without cardiovascular 
disease 
1.6-3.2  CAC Incidence of CAC  
– 6.1% per year in women and 
14.8% per year in men  
Progression  
– 17% per year in all participants, 
65% greater adjusted risk of 
progression in diabetic 
participants  
Detrano, et al. (2008)
32
 6,722 men and women 
in a population-based 
sample without a 
cardiovascular disease 
at entry (four 
racial/ethnic groups 
(Caucasian, black, 
hispanic, chinese) 
3.8  CAC 
Doubling CAC 
All four racial/ethnic groups; 
-15-35% increased risk for a 
major coronary event 
-18-39% for any coronary event 
ARIC, Atherosclerosis Risk in Communities Study; MESA, Multi-Ethnic Study of Atherosclerosis; CAPS, Carotid 
Atherosclerosis Progression Study; CHS, Cardiovascular Heart Study; CLAS, Cholesterol Lowering Atherosclerosis 
Study 
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Table 3. Clinical trials with EBCT 
Author, year Study population Follow
-up 
Exposure variable Outcome and results 
Achenbach S, 
et al. (2002) 
34
 
66 patients with 
coronary calcifications 
in EBT, 
LDL>130mg/dL  
14  Cervastatin (0.3mg/d)  Significantly difference (p=0.01) 
in the median annualized absolute 
and relative coronary calcium 
scores   
Nissen SE, et 
al (2004) 
35
 
A double-blind, 
randomized active 
control multicenter 
trial, in 654 patients  
18  Intensive (atorvastatin  
80mg) vs. Moderate 
(pravastatin 40mg)  
Intensive treatment with 
atorvastatin (no progression, -
0.4%[-2.4%~1.5%, p=0.98]) 
reduced CAC progression as 
compared with pravastatin (2.7% 
progression [0.2%~4.7%], 
p=0.001)  
Arad Y, et al. 
(2005) 
36
 
A double-blind, 
placebo-controlled, in 
1,005 healthy adults 
ages50-70 years with 
CAC≥80
th
 for age & 
gender  
51  Atorvastatin20mg/d+Vi
tC1g/d+VitE1000IU/d+
Aspirin81mg/d  vs. 
placebo+aspirin 81mg/d  
No difference on CAC 
progression (P=0.80), no 
significant reduction  of all 
atherosclerotic cardiovascular 
disease  (6.9% vs. 9.9%, p=0.08)  
Hecht HS, et 
al. (2003) 
37
 
A prospective study,  
182 asymptomatic 
patients without 
cardiovascular disease  
14  More (≤80) vs. less 
(>80 mg/dl) aggressive 
LDL cholesterol 
lowering txts  
No difference in calcified plaque 
progression (9.3%/year vs. 
9.1%/year)  
Schmermund 
A, et al. 
(2006) 
40
 
A multicenter, 
randomized, double-
blind trial, 471 patients 
with no history of 
cardiovascular disease  
12   Intensive (atorvastain 
80mg/d) vs. standard 
(atorvastatin 10mg/d)  
No difference on the CAC 
progression (27% vs. 25%, p=NS)  
Raggi P, et al. 
(2005)
39
  
A double-blind, 
multicenter trial in 615 
hyperlipidemic, 
postmenopausal women  
12  Intensive (atorvastatin 
80mg/d) vs. moderate 
(pravastatin 40mg/d)  
No difference - Calcium volume 
scores (CVS) (median 15.1% vs. 
14.3%, p=NS)  
Houslay ES, 
et al. (2006) 
38
 
Double-blind 
randomized controlled 
trial, 102 patients with 
calcific aortic stenosis 
and CAC  
24  Atorvastatin 80mg/d vs. 
placebo  
No difference in the rate of 
change in CAC (26%/yr vs. 
18%/yr) (95%CI -3% to 18%, 
p=0.18)  
1.2.3 n-3 and n-6 Polyunsaturated fatty acids 
Two essential fatty acids, which are alpha-linolenic acid (18:3n-3, n-3 fatty acid) and linoleic 
acid (18:2n-6, n-6 fatty acid), transform via desaturation (adding double bonds) and elongation 
(adding carbon atoms) into the longer-chain of polyunsaturated fatty acids. As noted from the 
name, the human body cannot produce and needs to obtain from foods. These essential fatty 
acids have imperative biological functions in developing and growing cell membranes, skin, 
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brain, and heart, as well as in producing local hormone, including prostaglandins and 
leukotrienes.
44
  
The main food sources for alpha-linolenic acid (n-3 fatty acid) are usually plant oils, for 
example, flaxseed, walnut, or dark green leafy vegetables. EPA and DHA, the longer carbon 
chain of polyunsaturated fatty acids, come from having salmon, tuna, halibut, and trout. The 
main sources of linoleic acid (n-6 fatty acid) are plant seed oils (e.g. oils of safflower, corn, and 
sunflower). 
 
 
Figure 1. n-3 and n-6 fatty acids 
[From Prog Lipid Res 2008;47:147-55 with permission from Dr. Gerd Schmitz
45
 ] 
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1.2.4 CHD associated with n-3 and n-6 fatty acids 
1.2.4.1   Marine n-3 fatty acids and CHD 
Many previous studies have shown that marine n-3 fatty acids (i.e. EPA or DHA) have beneficial 
and therapeutic effects against CHD, via modulating dyslipidemia such as reducing 
triglyceride
46
, lowering blood pressure
47
, reducing thrombosis
48
, and inhibiting vascular smooth 
muscle cell proliferation
49
.  
Several clinical trials of n-3 fatty acids, the Diet and Reinfarction Trial (DART), the Diet 
and Angina Randomized Trial (DART2), the Gruppo Italiano per lo Studio della Sopravvivenza 
nell‟Infarto miocardico-Prevenzione Trial (GISSI-Prevenzione Study), the Japan EPA Lipid 
Intervention Study (JELIS), and one observational study, the Japan Public Health Center-based 
study cohort I (JPHC) are summarized as following. 
The DART, a secondary prevention trial among 2,033 men in Wales who were diagnosed 
with MI, studied whether physicians‟ advice to eat oily fish such as mackerel, herring, kipper, 
pilchard, sardines, salmon, or trout, by more than two servings per week (200-400 g/week) or to 
take fish oil supplementation (called „Maxepa‟ capsule of 170mg EPA+115mg DHA) by three 
capsules per day could reduce the risk of cardiovascular events. For its two years of follow-up, 
the treatment group showed risk reduction on all-cause mortality by 29% (95%CI 0.54-0.92) and 
on ischemic heart disease by 16% (0.67-0.93), as compared to no dietary advice.50 On the other 
hand, the DART2, a subsequent secondary prevention trial with a 3-9 year follow-up, did not 
show benefits from dietary advice,51 with lower compliance over a longer follow-up period.  
The GISSI-Prevenzione Study, a large multi-center secondary prevention trial, found 
benefits of n-3 fatty acid in 11,323 men in Italy within three months of a heart attack event. The 
main finding showed significant risk reduction in all-cause mortality or non-fatal MI/stroke 
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[relative risk (RR)=0·85(0·74–0·98)].52 A time-course analysis, to examine how quickly this 
benefit could be effective to reduce the risks of total mortality and sudden death, found that even 
only after three months with n-3 PUFA exerted to reduce 41% of the risk for total mortality, and 
after four months 53% of the risk for sudden death.
53
 These two trials of the DART and GISSI 
studies suggested benefits of reducing the risk for arrhythmia and sudden cardiac death, which 
are fatal CHD events.  
Two recent large clinical trials in Japan indicated that habitual marine-derived n-3 fatty 
acids could reduce the risk for non-fatal events, which suggested anti-atherosclerotic effects. The 
Japan EPA Lipid Intervention Study (JELIS) was conducted among 18,645 hypercholesterolemic 
patients (with and without coronary artery disease (CAD)) for 4.6 years to examine whether 
either EPA (1800 mg/day) plus statin vs. statin only could prevent major coronary events. The 
treatment group showed a 19% risk reduction on major coronary events as compared to those 
with only a statin. Since both groups took stains, the finding was independent of cholesterol 
changes. Those who had a CAD history appeared to reduce the risk by 19%, and those without 
CAD at their enrollment showed risk reduction by 18%.
54
    
The other Japan study, the Japan Public Health Center-based study cohort I (JPHC), was 
a large prospective study for 5 years and examined whether high habitual fish intake could 
reduce CHD risk, in 41,578 Japanese adults ages 40-59 with no cardiovascular disease and 
cancer at enrollment.55 The highest quintile of fish intake (180 g/d vs. lowest 23g/d), as compared 
to the lowest quintile, showed a significant dose-response relationship on the risk reduction for 
nonfatal coronary events [0.43, (0.23-0.81)] but not for fatal events [1.08, (0.42-2.76)]. Together, 
many clinical trials and epidemiological observational studies consistently demonstrated 
cardioprotective effects of n-3 fatty acids, including fatal as well as non-fatal events.  
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Table 4. n-3 PUFA and cardiovascular disease in clinical trials 
Author, year, 
Study name 
Study population/ 
Study design 
Follow-
up(year) 
Exposure/ 
Supplementation 
Outcome 
Burr ML, et 
al. (1989)
50
 
 
DART 
2,033 men who 
recovered from MI 
under 70 years 
2 1) Fish advice- to intake at 
least two weekly servings of 
oily fish (200-400g/wk) or 
three fish oil capsules/day 
2) fat advice – to reduce fat 
intake up to 30% of total 
energy and to increase 
PUFA/saturated ratio to 1.0  
3) fiber advice – to increase 
cereal fiber to 18g/d 
4) as compared to no advice 
All-cause mortality 29% reduction  
(95%CI 0.54-0.92) as compared to 
no dietary advice group 
Ischemic heart disease 16% 
reduction (0.67-0.93) 
Burr ML, et 
al. (2003)
51
  
 
DART2 
3,114 men with angina 
under the age of 70 
(Recruiting phase I: 
1,111, phase II: 2,003) 
3-9 * Higher risk in the fish advice 
group than that in no advice 
Cardiac death HR=1.26 (1.00-1.58) 
Sudden cardiac death 1.54(1.06-
2.23) 
GISSI-
Prevenzione 
Investigators 
(1999) 
52
 
GISSI-
Prevenzione 
Trial 
11,324 survivors from 
recent MI (≤3months) 
/ a open-label design 
 
3.5 Four groups + 
pharmacological treatment 
and lifestyle advice 
1) n-3 PUFA 1g/d (850-882 
mg/d EPA+DHA) (n=2,836) 
2) vitamin E 300mg/d 
(n=2830) 
3) both (n=2,830) 
4) none (n=2,828) 
Death, non-fatal MI, and non-fatal 
stroke 15% risk reduction (95%CI 
0.74-0.98) 
CVD death, non-fatal MI, and non-
fatal stroke 20% risk reduction 
(0.68-0.95) 
Marchioli R. 
et al.(2002)
53
 
GISSI-
Prevenzione 
Trial 
11,324 post-MI 
(≤3months) patients  
/ a open-label design 
 
3.5 After 3 months of treatment 
Total mortality RR=0.59 (95%CI, 
0.36-0.97) 
After 4 months  
Sudden death RR=0.47 (0.22-0.99) 
GISSI-HF 
investigators 
(2008)
56
 
 
GISSI-HF 
6,975 patients with 
chronic heart failure in 
Italy / placebo-
controlled for all 
participants blinding 
3.9 3,494 patients with HF with 
1g/d EPA+DHA (850mg), 
vs. 3,481 placebo patients 
 
All-cause mortality HR=0.91 
(0.833-0.998) 
Death or admission to hospital for 
cardiovascular reasons HR=0.92 
(0.849-0.99) 
Yokoyama 
M, et al. 
(2007) 
54
 
 
JELIS 
18,645 
hypercholesterolemic 
(total-C ≥6.5 mmol/L 
or 251mg/dl) Japanese 
men/  a prospective, 
open-label, blinded 
end point evaluation 
4.6 
(1996-
2004) 
EPA 1.8g/d plus stain vs. 
statin-alone therapy 
 
3,664 CAD patients, of 
these, 1,050 with a MI event 
In all participants, for major 
coronary events 19% risk reduction 
[Secondary prevention] 
Coronary events - 19% risk 
reduction HR=0.81 (0.69-0.95)  
[Primary prevention] 
HR= 0.82 (0.63-1.06) 
Iso H. et al. 
(2006)
55
 
 
JPHC  
41,578 Japanese men 
and women ages40-59 
years without 
cardiovascular disease 
and cancer 
477,325 
person-
year 
(From  
1990-
1992 to 
2001) 
High fish intake [(highest 
quintile, 180 g/d or 
8times/week) vs. (lowest, 
23g/d or once a week)] 
*Quintile category 
1) Total CHD  HR=0.63 (0.38-1.04) 
2) Definite MI         0.44 (0.24-0.81) 
3) Sudden death      1.14 (0.36-3.63) 
[Nonfatal coronary events] 
HR=0.43 (0.23-0.81) 
[Fatal coronary events] 
HR=1.08 (0.42-2.76) 
*Continuous-Inverse associations 
1) Definite MI HR=0.35 (0.18-0.66) 
2) Non-fatal coronary events 
HR=0.33 (0.17-0.63) 
HR=Hazard ratio; OR=Odds Ratio; MI=myocardial infarction; EPA, eicosapentaenoic acid (20:5n3); DHA, docosahexaenoic 
acid (22:6n3); DART=Diet And Reinfarction Trial; DART2=Diet and Angina Randomized Trial; GISSI=Gruppo Italiano per lo 
Studio della Sopravvivenza nell‟Infarto miocardico-Prevenzione trial; HF=Heart Failure; JELIS=the Japan EPA Lipid 
Intervention Study; JPHC=Japan Public Health Center-Based study cohort 
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Table 5. n-3 PUFA and cardiovascular disease in observational studies 
Author, year, 
Study name 
Study design/  
Study population 
Exposure Outcome 
Hu F. et al. 
(2002)
57
 
 
Nurses‟ health 
study 
Prospective cohort study (16 yrs), 
84,688 women ages34-59 years 
without known cardiovascular risk 
factors 
Fish intake 
frequency  
(high intake  
vs.  rare fish 
<1 per month 
[reference 
group]) 
Significantly reduced relative risks for CHD 
death relative risk (RR) 
 1-3 times/month  0.79 (0.64-0.97)  
 Once/week  0.71 (0.58-0.87)  
 2-4 times/week 0.69 (0.55-0.88)  
 ≥5 times/week 0.66 (0.50-0.89)  
Trend in the quintiles of fish intake (p<0.001) 
Guallar E, et 
al. (1995)
58
 
 
Physicians‟ 
Health Study 
Nested case-control study/ 14,916 
participants  
Case: one with MI within first 5 
years of follow-up 
Control: ones without CHD who 
were matched by smoking and age 
Plasma levels 
of fish oils  
No significant difference on relative risks of 
EPA+DHA  
 in cholesterol esters 1.05(0.92-1.19) 
 in phospholipids 1.06 (0.80-1.40) 
Albert CM, et 
al (1998)
59
 
 
Physicians‟ 
Health Study 
Prospective cohort study (11 years 
of follow-up), 
20,551 male physicians ages40-84 
years without MI, cerebrovascular 
disease, and cancer at baseline  
Regular fish 
consumption 
(≥1 meals of 
fish/week)  
vs. less than 
once a month  
Sudden deaths 52% reduction (RR=0.48, 
95%CI 0.24-0.96): Fish intake (at least 
once/week) was significantly associated with 
reduced risk of total mortality, but not for total 
MI, non-sudden death, or total cardiovascular 
mortality  
Ascherio A, et 
al. (1995)
60
 
 
Health 
Professional 
follow-up 
Study 
Prospective cohort study (6 years 
of follow-up) 
44,895 male health professionals 
ages40-75 without known 
cardiovascular disease  
n-3 fatty acid 
intake from 
dietary 
questionnaires  
 
No significant association  
 (highest quintile vs the lowest of n-3 fatty 
acid intake)  CHD relative risk=1.12 
(0.96-1.31) 
 (≥6servings of fish/week vs. 
≤1serving/month) CHD 1.14 (0.86-1.51) 
 Death from coronary disease 
(eat fish vs. eat no fish) 
0.74 (0.44-1.23) 
Simon JA, et 
al. (1995)
61
 
 
MRFIT 
Nested case-control study, in the 
usual Care group 
Case:94 men with incident CHD 
during average 6.9 yrs of follow-up 
Control: 94 men without incident 
CHD matched on age, date of 
randomization, and clinic center 
Phospholipid 
n-3 fatty acid 
docosapentaen
oic acid  
[n-3 fatty acid doxosapentaenoic acid] 
CHD risk OR=0.58 (95%CI  0.38-0.89), with 
adjusting for total plasma cholesterol  
 
[Docosahexaenoic acid] 
CHD risk OR=0.57 (95%CI 0.36-0.90), with 
adjusting for HDL/LDL 
Daviglus ML, 
et al. (1997)
62
 
 
Western 
Electric Study 
Prospective cohort study (30years 
of follow-up), 
1822 men ages40-55 years without 
cardiovascular disease at baseline 
Fish 
consumption 
from a detailed 
dietary history 
[Fish intake ≥35g/day vs. 0g/day ] CHD death  
HR=0.62(0.40-0.94) 
MI death    0.56 (0.33-0.93) 
[Fatal/non-fatal]  Non-sudden death from MI -
significant   0.33 (0.12-0.91) /  Sudden death 
from MI  0.68 (0.37-1.25) 
OR=odds ratio; RR=relative risk; CI=confidence interval; MRFIT=Multiple Risk Factor Intervention Trial;  
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1.2.4.2  n-6 Polyunsaturated fatty acids and CHD 
In a Western diet, the most part of PUFA (about 90%) is comprised of n-6 fatty acids.
63
 High n-6 
fatty acids levels have been controversial, because several eicosanoids produced from 
arachidonic acids have proinflammatory and prothrombotic effects. However, recent studies 
found that arachidonic acid also produces eicosanoids with beneficial effects, including 
vasodilation, inhibition of platelet aggregation, and anti-inflammatory actions.
64
 In addition, 
recent researchers suggested that AA does not have a direct link to increase CHD risk, because it 
may be tightly regulated in the human body.
65-67
    
Several epidemiological studies showed the beneficial effects of n-6 fatty acids on CHD 
events. Prospective studies of the Kupio Heart Study
68
 and the Nurses‟ Health Study69 found risk 
reductions with higher linoleic acid on cardiovascular events. Based upon a 20-year follow-up 
study, the Nurses‟ Health Study reported the cardioprotective effect of linoleic acids.69  
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Table 6. Association between n-6 and CHD 
Author/Year Study design/  
Study population 
Follow-
up(year) 
Exposure Results 
Oh K, et al. 
(2005) 
69
 
 
Nurses‟ Health 
Study 
Prospective cohort study, 
78,778 US women 
without cardiovascular 
disease and diabetes at 
baseline 
20 With food 
frequency, 
Linoleic acid 
(the highest vs. 
the lowest 
quintile) 
 
CHD risk 25% reduction (95% CI 
0.62-0.95) (p-value for trend =0.01) 
[Stronger inverse associations] 
 Younger than 65 years 
 ≥25kg/m2 BMI 
Mozaffarian D, et 
al. (2005)
70
 
Health 
Professionals 
Follow-up Study 
Prospective cohort study, 
45,722 men without 
cardiovascular disease at 
baseline 
 
14 With food 
frequency 
questionnaires  
n-3 fatty acids to decrease 40-50% 
risk of sudden death, regardless of n-
6 fatty acids.  n-6 PUFA intake does 
not have adverse or opposite effect of 
n-3 PUFA on the risk of CHD events 
Laaksonen DE, et 
al. (2005)
68
 
Kupio Ischemic 
Heart Disease 
Risk Factor 
(KIHD) study  
Prospective cohort study, 
1,551 middle aged men 
without a history of 
cardiovascular disease, 
diabetes, or cancer at 
baseline 
1 4-day food 
record & 
serum fatty 
acid 
Linoleic acid RR=0.39 (0.21-0.71) 
 
*Both serum and dietary fatty acids 
ascertainments 
Iso H, et al. 
(2002)
71
 
 
Prospective nested case-
control study, 7,450 
Japanese women and men 
ages40-85, 
3 controls per case by 
matching for sex, age, 
community, year of serum 
storage, and fasting status 
By 1998, 
(from 
1984-1989, 
from  
1989-1992) 
Use of frozen 
serum samples 
Multivariate odds ratios 
1-SD increase in linoleic acid  
Total stroke OR=0.72 (0.59-0.89) 
Ischemic stroke 0.66 (0.49-0.88) 
Lacunar infarction 0.63 (0.46-0.88) 
Hemorrhagic stroke 0.81 (0.59-1.12) 
Dolecek TA. 
(1992) 
72
 
 
MRFIT 
Nested a clinical trial, 
12,866 middle-aged men 
in high risk for 
developing CHD, based 
upon smoking, diastolic 
blood pressure, and serum 
cholesterol  
From the usual care arm 
in the MRFIT study 
10.5 Four dietary 
recall 
interviews at 
baseline and 
follow-up 
years 1,2,3. 
Linoleic acid 
(the highest vs. 
the lowest 
quintile) 
No significant association with 
mortality for linoleic acid HR=0.58 
(P<0.10) 
Pietinen P, et al. 
(1997)
73
 
Alpha-
Tocopherol, 
Beta-Carotene 
Cancer 
Prevention Study 
Nested in a randomized 
double-blind placebo-
controlled trial, 
21,930 smoking men 
ages50-60 without 
cardiovascular disease at 
baseline 
6.1 Dietary 
questionnaire  
No significant association between 
linoleic acid and CHD – 
Multivariate relative risk (RR) 
(the highest vs. the lowest quintile) 
RR=0.92 (95%CI 0.56-1.50) 
p-value for  trend = 0.674 
TG=triglycerides; Tx=treatment; RCT=randomized clinical trial; PUFA=polyunsaturated fatty acids; 
DHA=docoxahexanoic acids; EPA=eicosapentaenoic acids; OR=odds ratio; RR=relative risk; CI=confidence 
interval; MRFIT=Multiple Risk Factor Intervention Trial; KIHD=the Kuopio Ischemic Heart Disease Risk Factor 
study 
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1.2.5 PAI-1 associated with n-6 fatty acids 
Plasminogen activator inhibitor-1 (PAI-1), which is a primary inhibitor of plasminogen 
activators, has an anti-fibrinolytic function.
74
 Thogersen et al. demonstrated that high plasma 
PAI-1 levels are associated with a high risk for a first acute myocardial infarction (AMI) in 
middle-aged men and women,
75
 suggesting that PAI-1 is an independent risk factor for CHD. 
PAI-1 levels are involved in local platelet activation or aggregation as an acute reactant. 
Additionally, PAI-1 is associated with obesity
76
 and type 2 diabetes
77
. 
 
Table 7. Association between n-6 fatty acids and PAI-1 in clinical trials 
Author/Year 
Study population/ 
Study design 
Regimen Results 
Fleischman 
AI, et al. 
(1975)
78
 
20 men and 46 
women from a 
geriatric center 
ages 60-109 years  
- 32g/day (actual fat daily 25/6g) 
- Unsaturated diet in highly 
unsaturated margarine for 2 weeks  
vs.  
a saturated diet in butter for 2 
weeks  
Linoleic acid intake  
from 2.89±0.11 (% of energy) for 2 wks  
to 5.00±0.26 (% of energy) for 2 wks was 
associated with different aggregation time 
(doubling, p-value<0.05) and 
disaggregation time (halving, p<0.01) 
Significant platelet aggregation activity 
differences associated with linoleic acid  
O'Brien JR, 
et al. 
(1976)
79
 
39 men ages 23-
53  
(case-19, control-
20) 
Partial replacement by linoleic acid 
(with sun-flower based product 
upto 65% linoleic acid) for 8 
weeks 
Decreased platelet activity 
 Platelet count between PUFA group 
(case) and control (p-value: 0.01) 
 Cholesterol (mg/dl) between PUFA 
group (case) and control (p-value: 0.01)  
Hornstra et 
al. (1973) 
80
 
Case- 69 men 
(with high 
polyunsaturated 
and low saturated 
fatty acids)  
Control -79 men 
(normal) 
One group with a polyunsaturated 
diet (linoleic acid approx. 12 % of 
total calorie)  
vs. 
The other group with a saturated 
diet (normal finnish diet, i.e., 
linoleic acid 4%) 
Significantly decreased aggregatability of 
platelets (including Aggregation-times) 
observed in those who had a regimen of 
high polyunsaturated and low saturated fat 
diets (p-value <0.001) 
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Table 8. Association between arachidonic acid (AA) and PAI-1 
In vitro studies 
Author 
/Year 
Experimental 
material 
Regimen Results 
Bates EJ, et 
al. (1995)
81
 
Neutrophils from the 
heparinised blood of 
healthy volunteers  
18 carbon fatty acids 
containing 1-4 double 
bonds 
AA may have a pro-inflammatory effect 
The bigger number of double bonds and the 
longer chain fatty acids, the more promoted in 
neutrophil adherence to endothelial cells 
The n-3 fatty acids stimulate less neutrophil 
adherence than the n-6 isomers 
Badwey JA, 
et al 
(1981)
82
 
Human neutrophils 
were purified from 
blood  
Adding the concentration 
of Arachidonate (110µM) 
to human neutrophils 
result in the maximum 
rate of superoxide (O2
-
) 
production  
AA stimulated human neutrophils to generate 
increased superoxide production 
Human clinical trials 
Author 
/Year 
Study population/ 
Study design 
Regimen Results 
Nelson 
GJ, et al. 
(1997)
83
 
A single blind 
crossover study, 
10 Healthy male 
subjects 
1.5 g/days dietary AA 
supplements for 50 days 
and 210mg/day normal 
diet for 65 days 
No changes in blood coagulation and thrombotic 
tendencies, as compared to those without 
supplement diet  
(non-significances) 
Katsumoto 
et al. 
(2007)
84
 
In a double-blind, 
placebo-controlled 
study, 24 healthy 
Japanese men with 
high habitual intake of 
fish oils 
860 mg/d AA for 4 wks After 2weeks, serum AA concentration 9.6 to 
13.7 g/100g total fatty acids (p<0.001) 
Until 4 weeks, this increase was maintained but 
after wash-out period came back to baseline level 
Lahoz C, 
et al. 
(1997)
85
 
42 healthy subjects (18 
women and 24 men) 
17-71 years,  
5 weeks 
According to different fat 
saturation, 
1) Saturated fatty acid 
2) Monounsaturated  
fatty acid 
3) Polyunsaturated fatty 
acid (PUFA, n-6) 
4) PUFA, n-3 
Effects of dietary fat saturation on  
 eicosanoid urinary excretion –no difference 
on prostaglandin, but significant difference 
on the excretion of thromboxane B2 
(p=0.0001) 
 platelet aggregation (PA) –a significant 
difference (p<0.05) 
 Systolic and diastolic BP were both 
significantly higher on saturated fatty acid 
than other three diets (p<0.0001) 
Animal studies 
Author 
/Year 
Study population/ 
Study design 
Regimen Results 
Koskelo et 
al. (1997) 
Sprague-Dawley rats 
(20/sex/group) for 90 
days, 1.0 & 2.5 g/kg/d  
In the ester form No signs of toxicity in rats supplemented with 
supplements with high as 2.5 g/kg/d 
Whelan J, 
et al. 
(1993)
86
 
24 male Golden 
Syrian hamsters (85-
110 g) into 4 groups 
(6 hamsters per group) 
10g/day for 3 weeks 
(~102g fat/kg diet)   
1) oleic acid  
(served as control) 
2) linoleic acid 
3) arachidonic acid 
4) eicosapentaenoic acid 
No effect on platelet aggregation according to 
fatty acid composition of the diet 
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1.2.6 Vitamin D and cardiovascular diseases  
Vitamin D is stored in the body fat as fat-soluble and metabolized in the liver.
87
 Vitamin D 
undergoes two hydroxylation processes to activate in the body: 1) in the liver, vitamin D from 
dietary sources and sun exposure undergoes hydroxylation into 25(OH)D circulation in the 
blood; and 2) in the kidney, this 25(OH)D form is again hydroxylated into 1,25(OH)2D.
88
 These 
tightly regulated steps ensure that the excessive intake does not reflect a high degree of 
cumulative production.
89
   
Habitual fish intake is the major source of vitamin D among the Japanese men in Japan.
90
 
Many cross-sectional studies have shown strong associations between vitamin D deficiency and 
CHD risk. Vitamin D could have an enormous impact on decreasing CHD risk since it is 
inexpensive, accessible, and safe to use.    
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Table 9. Associations between vitamin D and both subclinical atherosclerosis as well as risk 
factors for cardiovascular disease in cross-sectional studies 
Author, year,  
study location 
Study population Exposure Outcome Results 
Reis JP, et al.
91
  
(2009),   
within the 
Rancho 
Bernardo Study 
654 adults ages55-96 
years without a history 
of coronary heart 
disease, 
revascularization, or 
stroke 
Serum 
25(OH)D 
(quintile) 
 
IMT Internal carotid IMT (Ptrend=0.022) 
but not common carotid IMT 
(Ptrend=0.834) decreased in a dose-
response relationship as 25(OH)D was 
increased  No associations of 
1,25(OH)2D with internal and 
common carotid IMTs 
Michos ED, et 
al. (2009)
92
 
 in the Old 
Order Amish 
(OOA) 
650 Amish participants  Serum 
25(OH)D 
(quartile) 
IMT 
CAC 
C-RP 
No association of serum 25(OH)D 
with IMT, CAC or C-RP  25(OH)D 
deficiency (defined as <20ng/ml) 
prevalence - 38.2%  (observed in 
winter) 
Pilz et al.
93
 
(2009) 
In the Hoorn 
Study 
Population-based 614 
persons from a follow-
up visit of the Hoorn 
study 2000-2001 
Serum 
25(OH)D 
(quartile) 
IMT No significant associations between 
25(OH)D and IMT in both partial and 
full adjusted models 
Scragg R, et al. 
(2007)
94
  
in the third 
NHANES III 
1988-1994 
12,644 people aged 
≥20 years, in 
community setting,  
1988-1994, excluding 
those on hypertensive 
medication 
Serum 
25(OH)D 
 
BP Significant inverse association for 
systolic BP, after adjusting for BMI 
(p<0.05)  This inverse association 
became greater in participants aged 
≥50 years than younger (p=0.021) 
Martins et al.
95
  
(2007)  in the 
third NHANES 
1988-1994 
7186 men and 7902 
women adults ages ≥20 
years 
Serum 
25(OH)D 
(fourth 
quartile vs. 
first 
quartile) 
Hypertension, 
Diabetes, 
Obesity, 
triglycerides 
Hypertension   OR = 1.30 
Diabetes           OR = 1.98 
Obesity            OR = 2.29 
High triglyceride OR = 1.47 
    Increased cardiovascular risk 
factors in lower vitamin D 
Ginde et al.  
2009  
Comparison of 
two NHANES 
18,883 adults in 
NHANES III and 
13,369 adults in 
NHANES 2001-2004 
25(OH)D  Decreased by 6 ng/mL from 1988-
1994 to 2001-2004 
IMT, intima media thickness; CAC, coronary artery calcification; C-RP, c-reactive protein; NHANES, national health and 
nutri1tion examination survey; OR, odds ratio; 
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Table 10. Associations between vitamin D and cardiovascular disease in case-control and 
prospective studies 
Author, year,  
study location 
Study 
population 
Follow
-up(yr) 
Exposure Outcome Results 
Melamed et al.
96
 
(2008)  
in the third 
NHANES 1988-
1994 
13,311 health 
participants in 
community 
8.7 25(OH)D 
(highest 
quartile vs 
lowest ) 
All-cause 
mortality 
(1806 deaths 
including 777 
from CVD) 
26% increased rate of all-cause 
mortality (mortality rate ratio 
1.26(95% CI 1.08-1.46)) 
de Boer IH, et al.
97
 
(2009)  
In the Multi-Ethnic 
Study of 
Atherosclerosis 
1370 (394 with 
and 976 without 
chronic kidney 
disease) 
3  25(OH)D 
 
Coronary artery 
calcification 
(CAC)  
-At baseline 
CAC 
prevalence, 
53% (723 out of 
1370 
participants) 
-Among those without CAC at 
baseline, 21% (135 out of 647) 
developed incident CAC 
-Lower 25(OH)D associate with 
increased risk for incident CAC 
Adjusted RR=1.23 (1.00-1.52),  
Giovanucci et al.
98
 
(2008) In Health 
Professionals 
Follow-up Study 
A nested case-
control study 
(1:2 matching), 
18225 men 40-
75 yr, without 
previous CVD  
10  Plasma 
25(OH)D 
 
Myocardial 
infarction  
(case: 454 non-
fatal MI or fatal 
CHD 
Control: 900 
matched for age, 
date of blood 
collection, and 
smoking)  
Adjusted hazards ratio HR= 2.09 
[95% CI 1.24-3.54, Ptrend=0.02] 
(as compared with ≥30 vs ≤15 
ng/ml), after adjusting for family 
history of MI, BMI, alcohol, 
physical activity, history of 
diabetes and hypertension, 
ethnicity, region, marine n-3 
intake, LDL & HDL cholesterol, 
triglyceride 
Wang et al,
99
 
(2008), 
 in Framingham 
Offspring Study 
1739, with no 
history of CVD  
5.4  Serum 
25(OH)D 
 
A first 
cardiovascular 
event (120 
incident event) 
HR 1.62 (95% CI 1.11-2.36), 
(≥15 vs. <15) low serum 
25(OH)D levels were associated 
with incident cardiovascular 
disease 
Forman JP, et al.
100
 
(2008), 
 in the Nurses‟ 
Health Study  
A nested case-
control study, 
1484 women 
ages32 to 52 
years,  
 Plasma 
25(OH)D 
(quartile) 
 
Incident 
hypertension 
(742 cases and 
742 controls)  
-matched on age, 
race, and month 
of blood 
collection 
-(highest quartile vs. lowest) 
Odds ratio 1.66 (95%CI 1.11-
2.48, Ptrend=0.01)  
-With adjusting for BMI, physical 
activity, family history of 
hypertension, oral contraceptive, 
parathyroid hormone, calcium, 
phosphorous, creatinine, and uric 
acid, vitamin D deficiency (<30 
ng/mL) OR=1.47 (95%CI 1.10-
1.97)  
Forman JP, et al.
101
 
(2007),  
From 2 prospective 
studies of the 
Health 
Professionals‟ 
follow-up study 
and the Nurses‟ 
Health Study 
613 men from 
the Health 
Professionals‟ 
follow-up study 
and 1198 
women from 
the Nurses‟ 
Health Study 
4-8  
 
 
 
 
 
 
Plasma 
25(OH)D 
(<15 
ng/ml vs. 
≥30 
ng/ml) 
 
Incident 
hypertension 
-Measured plasma 25(OH)D : 
6.13 (95%CI 1.00-37.8) in men, 
2.67 (1.05-6.79) in women,  
3.18(95%CI 1.39-7.29) in the 
pooled relative risk combined 
men and women using random-
effects model 
CVD, cardiovascular disease; RR, relative risk; 
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Table 11. Associations between Vitamin D and Cardiovascular disease in clinical trials 
Author, year,  
study location 
Study 
population 
Follow-
up 
Exposure Outcome Results 
Krause et al.
102
  
(1998)  
Randomized 
18 subjects 
with stage I 
hypertension 
(8 women, 
ages 26-66 
years)  
6 weeks  Three times 
a week full 
body UVB 
or UVA 
25(OH)D Significant reduction in 24-h 
ambulatory systolic and diastolic 
blood pressure in the UVB but 
not in the UVA group.  
In the UVB group, 162% increase 
in plasma 25(OH)D, but in the 
UVA group, relatively unchanged 
Margolis KL, 
et al.
103
 (2008) 
In the 
Women‟s 
Health 
Initiative Study 
Randomized 
trial, 36,282 
postmenopaus
al women 
Median 
7 years 
1g calcium 
plus 400 IU 
of vitamin 
D3 daily or 
placebo 
-systolic and 
diastolic blood 
pressure change 
- incidence of 
hypertension  
No effect of the intervention on 
BP or risk of hypertension 
Hsia J, et al.
104
 
(2007) 
 
Women‟s 
Health 
Initiative Study 
36,282 
postmenopaus
al women 
ages50-79 
years  
7 years 500mg 
calcium 
carbonate 
with 200 IU 
vitamin D 
twice daily 
 Coronary or 
cerebrovascular 
risk 
MI or CHD death - Hazard ratio 
1.04 (95%CI, 0.92-1.18)  
Stroke – HR 0.95 (0.82-1.10) 
 No significant difference 
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1.2.7 Associations between marine n-3 fatty acids and subclinical atherosclerosis 
Table 12. Associations between marine n-3 fatty acids and subclinical atherosclerosis 
Study Study 
design (yr) 
Study population Outcome Results 
ERA-JUMP Population-
based cross-
sectional 
study (2008)   
40-49 years old men the 
Japanese, Caucasian 
and Japanese American 
men without any 
clinical CVD and 
cancer 
CCS≥10  Only IMT in the Japanese in Japan appeared 
significant associations with marine n-3 fatty 
acids but not in the other two populations or 
for CAC in all three populations  
Rotterdam
105
 Cross-
sectional 
study  
(2010)  
1,570 asymptomatic 
participants aged ≥ 55 
years (average age was 
about 64 years old) 
from a population-
based prospective 
cohort study in the 
Netherlands 
CCS>10  Weak inverse associations between and CAC 
prevalence as compared to those with no fish 
intake (prevalence rate 0.87, 0.78-0.98 of 
mild and intermediate calcification associated 
with >19g/day of a fish intake). However, 
EPA and DHA intake did not show 
significant associations (PR 0.93 and 0.97, 
p>0.05) 
MESA 
(Multi-
Ethnic Study 
Atherosclero
sis) 
106
 
Cross-
sectional 
(2008) 
a population-based 
study of 6814 men and 
women ages45-84 years 
who are without clinical 
CVD from 6 U.S. 
communities 
CCS>0  Inverse association of dietary marine n-3 
PUFA intake (220 vs 40 mg/d) with common 
carotid IMT (highest quartile vs. lowest 
quartile OR=0.69 [0.55-0.86]) but not with 
CAC score (1.14 [0.94-1.38])  
CARDIA  
(Coronary 
Artery Risk 
Development 
in Young 
Adults)
107
  
Prospective 
population-
based 
multicenter 
cohort study 
(2007)  
5,115 African 
American and 
Caucasian participants 
ages33 to 45 years at 
baseline recruited from 
4 U.S. cities 
 
 Younger adults demonstrated risk factors for 
CAC as much as those for the elders.These 
young but being with higher risk factors had 
2-3 times more likely to have CAC. 
Particularly, smoking, LDL cholesterol, 
systolic blood pressure, and glucose were 
found significant risk factors for having 
CAC. 
 CCS, coronary calcium score; CAC, coronary artery calcification;  
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1.2.8 ERA-JUMP study   
The ERA-JUMP study has two surveys: the baseline (2002-2006) and the follow-up (2007-
2012). This population-based study was initiated to measure prevalence and risk factors for 
subclinical atherosclerosis in three different populations (i.e., Japanese, Caucasian, and Japanese-
American men) in order to reduce CHD. From 2002 to 2006, 926 participants aged 40-49 years 
were randomly selected from three study sites: 313 Japanese men from Kusatsu, Shiga, Japan; 
310 Caucasian men from Allegheny County, Pennsylvania, U.S.; and 303 Japanese-Americans 
from Honolulu, Hawaii, U.S. Excluded were those who had clinical cardiovascular disease or 
other severe illnesses. The Japanese men ages 40-49 years in Kusatsu city were randomly 
enrolled from the residents‟ registry for all Japanese nationals.5 The Caucasian men ages 40-49 
years were randomly enrolled from the voter registration list of Allegheny County 
5
 The 
Japanese-American men in the Hawaiian site, representing the third/fourth generations of 
Japanese immigrants with no ethnic admixture, were randomly selected among the offspring 
whose father participated in the Honolulu Heart Program
108
, a longitudinal follow-up study 
among Japanese-American men.
109
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2.1 ABSTRACT 
Objective: Epidemiological studies suggested that n-6 fatty acids, especially linoleic acid (LA), 
have beneficial effects on coronary heart disease (CHD), whereas some in vitro studies suggested 
that n-6 fatty acids, specifically arachidonic acid (AA), may have harmful effects. We examined 
the association of serum n-6 fatty acids with plasminogen activator inhibitor-1 (PAI-1).   
Methods and Results: A population-based cross-sectional study recruited 926 randomly 
selected men aged 40-49 without cardiovascular disease during 2002 to 2006 (310 Caucasian, 
313 Japanese, and 303 Japanese-American men). Plasma PAI-1 was analyzed in free form, both 
active and latent. Serum fatty acids were measured with gas-capillary-liquid-chromatography. To 
examine the association between total n-6 fatty acids (including LA and AA, respectively) and 
PAI-1, multivariate regression models were used. After adjusting for confounders, total n-6 fatty 
acids, LA, and AA were inversely and significantly associated with PAI-1 levels. These 
associations were consistent across three populations.  
Conclusions: Among 915 middle-aged men, serum n-6 fatty acids had significant inverse 
associations with PAI-1.  
 
Key words: plasminogen activator inhibitor-1; linoleic acid; fatty acids 
 
 27 
2.2 INTRODUCTION 
Plasminogen activator inhibitor-1 (PAI-1), a primary inhibitor of plasminogen activators, has an 
anti-fibrinolytic function.
74
 High levels of PAI-1 are associated with an increased risk for 
developing coronary heart disease (CHD) or stroke.
75, 110, 111
 This increased risk of CHD may be 
due to promoting platelet adhesion and acute thrombus formation.
75
 
Epidemiological studies suggest that linoleic acid (LA), a major component of n-6 fatty 
acid, has beneficial effects on both CHD and its risk factors, whereas some in vitro studies 
suggest that another n-6 fatty acid, arachidonic acid (AA), may have adverse effects. The 
Nurses‟ Health Study showed that a high dietary intake of LA has a strong inverse association 
with CHD.
69
 Additionally, a recent meta-analysis found that dietary intake of LA had a strong 
inverse association with non-fatal cardiovascular events.
112
 The cardioprotective benefits
68
 of n-6 
fatty acids may be due to decreasing blood pressure,
113
 reducing thrombosis,
114
 and improving 
insulin sensitivity.
115
 In contrast, several eicosanoids derived from AA are pro-inflammatory and 
pro-thrombotic, promoting vasoconstriction and enhance platelet aggregation. Thus, AA has 
been postulated to adversely affect CHD. However, recent studies identified AA-derived 
eicosanoids to have several beneficial attributes including vasodilation, platelet aggregation 
inhibition, and anti-inflammatory effects.
64
 Interestingly, a recent meta-analysis showed that AA 
was not associated with fatal or non-fatal cardiovascular events.
112
 These contradictory findings 
suggest that dietary or serum levels of AA have little association with CHD risk, possibly 
because AA levels are tightly regulated in the human body.
65-67
 Although PAI-1 is known to be 
involved in developing atherothrombosis,
116, 117
 very few studies reported their associations with 
n-6 fatty acids.    
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The purpose of this study was to test whether higher levels of serum n-6 fatty acids are 
associated with lower levels of PAI-1 in men aged 40-49. Additionally, we investigated whether 
higher levels of specific n-6 fatty acids, i.e., LA and AA, are associated with lower levels of PAI-
1. To test these hypotheses, we examined data from a population-based cross-sectional study of 
926 Caucasian, Japanese, and Japanese-American men aged 40-49 in the Electron-Beam 
Tomography, Risk Factor Assessment among Japanese and U.S. Men in the Post-World War II 
Birth Cohort (ERA-JUMP) study.
5
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2.3 METHODS 
2.3.1 Study population 
Participants were a randomly selected population-based sample of 926 men aged 40-49 between 
2002 and 2006 from three centers: 310 Caucasian men from Allegheny County, Pennsylvania, 
313 Japanese men from Kusatsu, Shiga, Japan, and 303 Japanese-American men from Honolulu, 
Hawaii. Those with clinical cardiovascular or other severe diseases were excluded. Detailed 
descriptions of the study population were previously published.
5, 108, 109
 Our final sample was 915 
men (304 Caucasian, 313 Japanese, and 298 Japanese-American men) due to 11 missing data. 
Informed consent from each participant was obtained. The protocol for the study was approved 
by the Institutional Review Boards of the University of Pittsburgh (Pennsylvania), Shiga 
University of Medical Science (Otsu, Japan), and the Kuakini Medical Center (Honolulu, 
Hawaii).   
Venipuncture was performed in all participants in the early morning after a 12-hour fast, 
as previously described.
5
 Fasting serum and plasma samples were stored at -80C, and shipped 
on dry ice to the Heinz Laboratory at the University of Pittsburgh to examine levels of low-
density lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc), total 
cholesterol, triglycerides, insulin, and glucose, as published elsewhere.
5
 A calorimetric-
competitive-enzyme-linked immunosorbent assay was utilized to assess CRP (C-reactive 
protein). Hypertension was defined as systolic blood pressure ≥140 mmHg, diastolic blood 
pressure ≥90 mmHg, or anti-hypertensive medication usage. Diabetes mellitus was defined as 
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fasting glucose level ≥7mmol/L (126mg/dL) or anti-diabetic medication usage. „Alcohol drinker‟ 
was defined as a man who drinks alcohol two days or more per week. „Current smoking‟ was 
defined as a man who smoked during the prior month. 
2.3.2 Measurement of plasminogen activator inhibitor-1  
As previously reported,
118, 119
 plasma PAI-1 was measured at the clinical biochemistry research 
laboratory of the University of Vermont.  Briefly, plasma PAI-1 levels were analyzed in citrated 
plasma
118
 by a two-site ELISA, which was sensitive to free PAI-1 form but not to complexes 
between t-PA and PAI-1
119
, which was developed by Dr. Collen and colleagues.
120
 Inter-assay 
coefficient of variations (CVs) for PAI-1 was 7.7%.  
2.3.3 Measurements of serum fatty acids 
To measure serum fatty acids in a percentage of total fatty acid amounts, gas-capillary-liquid 
chromatography (PerkinElmer Clarus 500; PerkinElmer, Waltham, MA) was performed.
6
 The 
intra-assay CVs of LA (18:2n-6) and AA (20:4n-6) in serum n-6 fatty acids were 1.6% and 2.8%, 
respectively.
6
 The CVs for other fatty acids ranged from 2.5% to 9.8%.
6
  
2.3.4 Statistical analyses  
Log-transformed PAI-1 was used for the analyses, because the distribution of PAI-1 was skewed. 
To compare descriptive distributions across centers, an analysis of variance (ANOVA) for a 
continuous variable and a Mantel-Haenszel test for a categorical variable were performed. When 
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a significant difference among the three groups exists, we examined multiple comparison tests 
using a Bonferroni test. To pool the data, we tested interactions according to centers on 
associations of PAI-1 with LA as well as AA. We also assessed the center-specific associations 
of n-6 fatty acids on PAI-1 according to the three study centers (Table 15). After confirming no 
interaction and the same direction of the associations by centers, we pooled the data. To estimate 
the association between serum n-6 fatty acids and PAI-1 levels, we performed multivariate linear 
regression analyses, adjusting for covariates as followings: in the model I, we adjusted for age 
and center; in the model II, we further adjusted for body mass index (BMI), current smoking, 
alcohol drinker, hypertension, and diabetes; in the model III, we further adjusted for LDLc, 
HDLc, triglycerides, and CRP; in the model IV, we further adjusted for marine n-3 and trans 
fatty acids. Because some eicosanoids of n-3 fatty acids were reported to inhibit the production 
of AA derived eicosanoids,
64
 we tested marine n-3 as well as trans fatty acids as covariates. The 
level of significance was considered to be p<0.05. All reported p-values were based on two-sided 
tests. All statistical analyses were performed using SAS 9.2 for Windows (SAS Institute, Inc., 
Cary, North Carolina, U.S.).  
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2.4 RESULTS 
General characteristics of the 915 study participants are shown in Table 13. The average age was 
45 years old. In the total study population, participants with hypertension and diabetes were 
24.9% and 7.5%, respectively. Median level (interquartile range) of PAI-1 was 37.4 ng/mL (23.3 
to 58.4).  
Serum proportions of fatty acids are listed in Table 14. Total n-6, total n-3, saturated, and 
monounsaturated fatty acids made up 39.0%, 6.5%, 31.2%, and 20.4%, respectively. LA and AA 
were 28.8% and 8.1%, respectively. A correlation coefficient between LA and AA was 0.06 
(p=0.0596).  
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Table 13. General characteristics of the study participants 
 
Total  
(n=915) 
Caucasian men 
(n=304) 
Japanese men 
(n=313) 
Japanese-
American men 
(n=298) 
Age (year) 45.4 ± 2.8 45.0 ± 2.8 45.1 ± 2.8
 †
 46.1 ± 2.8
 ‡ 
BMI (kg/m
2
) 26.5 ± 4.5 27.9 ± 4.3
 *
 23.7 ± 3.1
 †
 28.0 ± 4.6 
Waist circumference 
(cm) 
92.6 ± 12.0 98.7 ± 11.8
 *
 85.2 ± 8.1 
†
 94.0 ± 11.7
 ‡ 
Systolic blood pressure 
(mmHg) 
125.1± 13.6 122.6 ± 11.2 125.0 ± 16.1 127.6 ± 12.6
 ‡ 
Diastolic blood pressure 
(mmHg) 
75.8 ± 10.2 73.1 ± 8.6
 *
 76.5 ± 11.9 77.7 ± 9.3
 ‡ 
Hypertension  (%)  24.9 15.1
 *
 26.5 33.2
 ‡ 
LDL cholesterol (mg/dL) 129.5 ± 34.5 134.7 ± 33.6 132.2 ± 35.9
 †
 121.4 ± 32.5
 ‡ 
Triglyceride (mg/dL)§ 
140.5  
(96.0-224.0) 
128.0 
(92.0-185.5) 
137 
(103-182) 
140.5 
(96.0-224.0) 
HDL cholesterol (mg/dL)  50.9 ± 13.1 47.8 ± 12.8
 *
 54.1 ± 13.6
 †
 50.7 ± 12.2 
Total cholesterol (mg/dL) 212.0 ± 36.9 212.1 ± 37.7 217.2 ± 36.0
 †
 206.5 ± 36.4 
Glucose (mg/dL) 106.7 ± 18.4 101.3 ± 13.7
 *
 106.8 ± 18.7
 †
 112.0 ± 20.7
 ‡ 
Insulin (µIU/mL) 13.5 ± 7.9 15.2 ± 8.3
 *
 10.3 ± 4.4
 †
 15.1 ± 9.2 
Diabetes (%)  7.5 3.3 6.1
 †
 13.4
 ‡ 
Current smoker (%) 23.5 7.2
 *
 49.2
 †
 13.1 
Alcohol drinker (%) 49.6 44.1
 *
 67.1
 †
 36.9 
C-reactive protein (mg/l)§ 0.6 (0.3-1.3) 1.0 (0.5-1.8) 0.3 (0.2-0.7) 0.7 (0.3-1.3) 
PAI-1 (ng/mL)§ 
37.4  
(23.3-58.4) 
27.4  
(15.7-41.3)
 *
 
41.2  
(24.3-67.3) 
45.9  
(31.6-61.7)
 ‡ 
Mean ± SD. S.D.=standard deviation; 
Significance test was based on ANOVA, followed by Bonferroni test if the overall ANOVA was 
significant.  
* Under Bonferroni test, significant difference between Caucasian and Japanese men, p<0.01 
† Under Bonferroni test, significant difference between Japanese and Japanese-American men, 
p<0.01 
‡ Under Bonferroni test, significant difference between Caucasian and Japanese-American men, 
p<0.01 
BMI=body mass index; LDL=low density lipoprotein; HDL=high density lipoprotein;  
§ Median (interquartile range) 
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Table 14. Distribution of serum fatty acids (%)  
 
Total  
(n=915) 
Caucasian 
men 
(n=304) 
Japanese men 
(n=313) 
Japanese-
American men 
(n=298) 
Polyunsaturated fatty acids 45.4 ± 4.4 45.6 ± 4.5
 *
 44.3 ± 3.8
 †
 46.5 ± 4.7 
     Total n-6 fatty acids  39.0 ± 5.2 41.3 ± 4.1
 *
 34.7 ± 4.2
 †
 41.1 ± 4.3 
             Linoleic acid 28.8 ±4.5 29.9 ± 4.1
 *
 26.5 ± 4.1
 †
 30.0 ± 4.3 
     Arachidonic acid 8.1 ± 2.2 9.0 ± 1.9
 *
 6.6 ± 1.3
 †
 8.9 ± 2.3 
     Total n-3 fatty acids 6.5 ± 3.4 4.2 ± 1.8
 *
 9.6 ± 3.0
 †
 5.4 ± 2.3
 ‡ 
             Marine n-3 fatty acids 6.0 ± 3.4 3.8 ± 1.8
 *
 9.3 ± 3.0
 †
 4.9 ± 2.2
 ‡ 
             α-linolenic fatty acids 0.3 ± 0.3 0.3 ± 0.3 * 0.2 ± 0.2 † 0.4 ± 0.4 ‡ 
Monounsaturated fatty acids 20.4 ± 3.4 20.3 ± 3.2
 *
 21.2 ± 3.1
 †
 19.6 ± 3.6 
Saturated fatty acids 31.2 ± 2.3 30.9 ± 2.4
 *
 31.7 ± 2.2
 †
 30.9 ± 2.2 
Trans fatty acids 0.8 ± 0.4 1.0 ± 0.5
 *
 0.6 ± 0.2
 †
 0.9 ± 0.4
 ‡ 
Mean ± S.D. (standard deviation) 
Total n-6 fatty acids indicate the sum of linoleic acid (18:2n-6), gamma-linoleic acid (18:3n-6), 
dihomo-gamma-linolenic acid (20:3n-6) and arachidonic acid (20:4n-6).  
Marine-derived n-3 fatty acids were defined as eicosapentaenoic acid (20:5n-3), docosapentaenoic 
acid (22:5n-3), and docosahexaenoic acid (22:6n-3).  
Total n-3 fatty acids indicate marine-derived n-3 fatty acids, eicosatetraenoic acid (20:4n-3) and α-
linolenic acid (22:18n-3).  
Saturated fatty acids indicate the sum of myristic aicd (14:0), palmitic acid (16:0) and stearic acid 
(18:0).  
Monounsaturated fatty acids indicate the sum of palmitoleic acid (16:1n-7), oleic acid (18:1n-9), and 
cis-vaccenic acid (18:1n-7).  
Trans fatty acids indicate the sum of palmitelaidic acid (16n-7:1t), trans 9-octadecanoic acid (18n-
9:1t) and linolelaidic acid (18n-6:2tt).  
Significance test was based on ANOVA followed by Bonferroni test if the overall ANOVA was 
significant.  
* Under Bonferroni test, significant difference between Caucasian and Japanese men, p<0.01 
† Under Bonferroni test, significant difference between Japanese and Japanese-American men, 
p<0.01 
‡ Under Bonferroni test, significant difference between Caucasian and Japanese-American men, 
p<0.01 
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Pooled and center-specific analyses reveal that serum n-6 fatty acids were inversely 
associated with PAI-1 in the total population as well as in each of three different populations 
(Table 15). Pooled analyses showed that serum total n-6 fatty acids, LA, and AA had significant 
inverse associations with PAI-1 levels, even after adjusting for covariates. In center-specific 
analyses, PAI-1 had significant inverse associations with total n-6 fatty acids and LA over three 
study populations. These significant associations remained after multivariate adjustments. PAI-1 
was inversely associated with AA. No significant interaction existed in the associations of serum 
n-6 fatty acids, LA, and AA with PAI-1 according to the study centers (p=0.0857, 0.0832, and 
0.2373, respectively). Standard parameter estimates indicate a standard deviation (SD) unit 
change in log-transformed PAI-1 per a 1 SD unit increase in serum n-6 fatty acids.  
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       Table 15. Center-specific and pooled associations between n-6 fatty acids and log(PAI-1)  
 
Standardized parameter estimates 
Total 
(n=915) 
Caucasian men 
(n=304) 
Japanese men 
(n=313) 
Japanese-
American men  
(n=298) 
Total n-6 Fatty acids 
      Univariate -0.2674
*
 -0.3185
*
 -0.2452
*
 -0.2711
*
 
      Model I -0.3224
*
 -0.3184
*
 -0.2412
*
 -0.2711
*
 
      Model II -0.2390
*
 -0.1807
*
 -0.2006
*
 -0.2069
*
 
      Model III -0.1315
*
 -0.0642
*
 -0.1150
*
 -0.0996
*
 
      Model IV -0.1354
*
 -0.0899
*
 -0.1169
*
 -0.0903
*
 
Linoleic acid 
      Univariate -0.2346
*
 -0.2862
*
 -0.1952
**
 -0.2306
*
 
      Model I -0.2392
*
 -0.2870
*
 -0.1912
**
 -0.2306
*
 
      Model II -0.1708
*
 -0.1542
*
 -0.1494
*
 -0.1779
*
 
      Model III -0.1015
*
 -0.0659
*
 -0.0704
*
 -0.1180
*
 
      Model IV -0.1014
*
 -0.0819
*
 -0.0441
*
 -0.1140
*
 
Arachidonic acid  
      Univariate -0.1568
*
 -0.1299
***
 -0.1852
**
 -0.1081 
      Model I -0.1424
*
 -0.1314 -0.1849
**
 -0.1082 
      Model II -0.1010
*
 -0.0826
*
 -0.1680
*
 -0.0669
*
 
      Model III -0.0087
*
 -0.0031
*
 -0.0974
*
  0.0401
*
 
      Model IV -0.0087
*
 -0.0029
*
 -0.0966
*
 0.0372
*
 
*p<0.001;  **p<0.01;  ***p<0.05 
Total n-6 fatty acids indicate the sum of linoleic acid (18:2n-6), gamma-linoleic acid (18:3n-6), 
dihomo-gamma-linolenic acid (20:3n-6) and arachidonic acid (20:4n-6).  
Marine-derived n-3 fatty acids were defined as eicosapentaenoic acid (20:5n-3), docosapentaenoic 
acid (22:5n-3), and docosahexaenoic acid (22:6n-3).  
Total n-3 fatty acids indicate marine-derived n-3 fatty acids, eicosatetraenoic acid (20:4n-3) and 
α-linolenic acid (22:18n-3).  
Trans fatty acids indicate the sum of palmitelaidic acid (16n-7:1t), trans 9-octadecanoic acid (18n-
9:1t) and linolelaidic acid (18n-6:2tt).  
Model I: adjusted for age;  
Model II: additionally adjusted for BMI, current smoking, alcohol drinker, hypertension, and 
diabetes;  
Model III: further adjusted for LDL cholesterol, HDL cholesterol, triglycerides, and CRP (C-
reactive protein);  
Model IV: continuously adjusted for marine n-3 fatty acids, and trans fatty acids. 
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2.5 DISCUSSION 
This population-based cross-sectional study found that total serum n-6 fatty acids were inversely 
and significantly associated with PAI-1 among 915 men, aged 40-49. Additionally, both LA and 
AA showed significant inverse associations with PAI-1 levels (both, p<0.0001).  
Our present study may provide a novel mechanism on the cardioprotective benefits of n-6 
fatty acids by improving the fibrinolytic response, such as reducing PAI-1. Our finding of an 
inverse association between serum n-6 fatty acids and PAI-1 is consistent with the results of 
several previous studies,
78, 79
 but not all.
121
 These findings of n-6 fatty acids suggest a favorable 
fibrinolytic response on vascular thrombosis, including a decrease in platelet aggregation. 
Fleischman et al. found an increased platelet aggregation time (p<0.05) and a decreased 
disaggregation time (p<0.01) on a dietary LA in each for two weeks from about 2.9% to about 
5.0% of energy among 66 subjects.
78
 A crossover study by Thijssen et al. also demonstrated an 
increased platelet aggregation time while on a LA diet in comparison to on a saturated fatty acid 
diet in 18 men (p=0.04).
122
 O‟Brien et al. conducted a clinical trial in 39 healthy men for six 
weeks with either a PUFA diet (sunflower oil based foods, 65% LA) replaced for saturated fat or 
a normal diet.
79
 They found the decreased platelet count (p=0.01), and the increased bleed time 
(p=0.05).
79
 Further, previous studies, including the Nurses‟ Health Study,69 have suggested that 
n-6 fatty acids lower the CHD risk, through a decrease in blood pressure,
113
 a reduction of 
thrombosis,
114
 and an improvement in insulin sensitivity.
115
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Our results of the inverse association between serum n-6 fatty acids and PAI-1 are 
partially inconsistent with the results of a previous study.  Byberg et al. showed that PAI-1 
activity has a significant inverse association with serum LA but a significant positive association 
with serum AA in their sub-analysis with 381 men from a population-based cross-sectional 
sample of 871 men aged 70 years.
121
 The discrepancy in the association of PAI-1 with AA may 
be attributed to different measurements of PAI-1 and fatty acids or to different ages of 
participants. In measurements of PAI-1 and fatty acids, Byberg et al. measured PAI-1 activity 
(i.e., a free active form) and serum cholesterol ester for fatty acid measurements in older 
participants (mean average 70 years), whereas we measured total plasma PAI-1 levels (i.e., free 
active, free latent, and complex with t-PA forms) and fatty acids in serum cholesteryl ester, 
phospholipids, and triglycerides, in middle-aged men (ages 40-49). Although the previous study 
demonstarted a linear association between PAI-1 activity and PAI-1 antigen (r=0.80 in platelet-
poor plasma; r=0.88 in platelet-rich plasma), about 66.7% of PAI-1 antigen in plasma was 
active.
120
 Considering very short half-life of PAI-1 levels, and various processes (e.g., 
temperature, time, or pH) for handling the blood samples, as well as significant diurnal change of 
PAI-1, the PAI-1 antigen measurement as in our study may have the advantage of detecting 
comprehensive forms of relatively unstable total plasma PAI-1, rather than measuring only an 
active form.  
Future studies are required in order to elucidate possible reasons of the discrepancy 
between in vitro and the population studies. Several in vitro studies have shown that LA 
increases the secretion of PAI-1 in HepG2 cells.
123, 124
 In vitro studies reported that AA-produced 
eicosanoids promoted neutrophil adhesion
81
 and IL-1β production by human monocytes125. 
However, more recent studies demonstrated no effect or a beneficial effect. A double-blind 
39 
placebo-controlled study with an AA supplementation of 840 mg/day for four weeks 
demonstrated no effect on platelet aggregation in 24 healthy Japanese men who had relatively 
high levels of fish oil consumption.
84
 In another clinical trial of 10 healthy men taking a 
200mg/day vs. 1,500mg/day AA regimen, Nelson et al. found a borderline significance between 
higher AA intake and prolonged bleeding time (p=0.06).
83
 Although several AA-derived 
eicosanoids may indeed have a pro-inflammatory role, recent studies suggest that several AA-
derived eicosanoids may play an anti-inflammatory role.
45
   
Mechanisms responsible for the association of n-6 fatty acids with PAI-1 require future 
studies. However, two possibilities exist. First, n-6 fatty acids may delay platelet aggregation so 
that PAI-1, acting as an acute-phase reactant, is decreased within hemodynamic balance and 
thrombotic response, during vascular injury, in atherosclerosis and CHD. Several previous 
studies have shown that LA reduces platelet aggregation.
78, 79
 Second, LA may reduce PAI-1 
levels through its cholesterol lowering effect. A previous study from ERA-JUMP found that 
higher levels of serum LA and AA were associated with lower levels of LDL and VLDL.
126
 An 
in vitro study showed that VLDL led to increased PAI-1.
127
 These reduced cholesterol levels 
may improve or modulate the fibrinolytic response.  
The strengths of the present study include the following: a) the association was examined 
in a randomly selected population-based sample; and b) the sample size was relatively large. 
However, this study also has several limitations: a) the cross-sectional study design could not 
assess a causality; b) the study population included only men aged 40-49 years, which may limit 
the generalizability to other populations; and c) as an observational study, this present study may 
include residual confounding or potentially unmeasured factors, such as total energy intake.
128
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In conclusion, serum n-6 fatty acids were inversely and significantly associated with PAI-
1 levels in a population-based cross-sectional study. Total n-6 fatty acids, especially LA and AA, 
were inversely and significantly associated with PAI-1 levels in both univariate and multivariate 
models. These findings suggest that n-6 fatty acids may have favorable effects on fibrinolysis. A 
future study to examine the causality between n-6 fatty acid and PAI-1 is warranted.   
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3.1 ABSTRACT 
Background: Previous studies have shown that vitamin D deficiency increases the risk for 
coronary heart disease (CHD). However, results on the association on subclinical atherosclerosis 
associated with vitamin D deficiency are inconsistent. We hypothesized that the vitamin D levels 
among Japanese men would be higher than the levels among Caucasian and Japanese-American 
men, due to the Japanese habitual intake of fish, which is a major food source of vitamin D. We 
further hypothesized that vitamin D deficiency would be associated with subclinical 
atherosclerosis. 
Methods and Results: In a population-based cross-sectional study, 295 men aged 40-49 years 
without cardiovascular and other severe diseases, were randomly selected from three study 
centers (99 Japanese men from Shiga, Japan, 98 Caucasian men from Allegheny County, PA, 
and 98 Japanese-American men from Honolulu, HI) from 2002 to 2006. We explored the vitamin 
D levels of the three populations and the association between vitamin D deficiency and 
subclinical atherosclerosis. A liquid chromatography-tandem mass spectrometry was utilized to 
measure the serum vitamin D, including both 25(OH) vitD2 and 25(OH) vitD3. Two 
measurements of subclinical atherosclerosis, intima-media thickness (IMT) by an ultrasound 
scan and coronary artery calcification (CAC) by an Electro-Beam-Computed-Tomography 
(EBCT), were examined in standardized protocols across all three centers. We utilized 
multivariate regression models to estimate the association of vitamin D deficiency (defined as 
25(OH)D<20 ng/mL) with IMT and logistic regression to estimate odds ratios on CAC (defined 
as coronary calcium score ≥10). The prevalence rates of vitamin D deficiency were 43.4% (43 of 
98) in Japanese men, 11.2% (11 of 98) in Caucasian men, and 9.2% (9 of 98) in Japanese-
47 
American men. In a univariate model, vitamin D deficiency showed a significant positive 
association with IMT only in Caucasian men (p=0.022). However, in multivariate models, 
vitamin D deficiency no longer showed a significant association with IMT. For the Japanese-
American men, vitamin D deficiency was significantly associated with CAC, even after adjusting 
for covariates (adjusted OR=8.02, 95%CI 1.38-46.62). 
Conclusion: In this population-based cross-sectional study, we found that the Japanese men 
showed lower serum vitamin D level than the Caucasian or the Japanese-American men. We 
further observed that vitamin D deficiency was not associated with either IMT or CAC, except 
for a few significant associations: Caucasian men had a significant association between vitamin 
D deficiency with IMT in a univariate model but not in multivariate models, and Japanese-
American men had significant associations between vitamin D deficiency and CAC in 
multivariate models.   
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3.2 INTRODUCTION 
Intima media thickness (IMT) of the carotid artery and coronary artery calcification (CAC), both 
highly reliable and non-invasive methods to measure subclinical atherosclerosis, have 
demonstrated strong associations with cardiovascular events.
15, 16, 129
 As a sensitive 
measurement, IMT can detect the relatively early stage of atherosclerosis.
19, 20
 CAC, based on a 
coronary artery calcium score as an independent predictor for CHD events,
130
 demonstrated 
strong associations with CHD risk factors.
129
  
Recent epidemiological evidence shows that vitamin D deficiency may increase the CHD 
risk. Cross-sectional studies with the National Health and Nutrition Examination Survey 
(NHANES) data
94-96, 131, 132
 and many prospective studies have reported that low 25(OH)D levels 
are associated with high CHD risk factors, including hypertension
94, 100, 101, 133
, glucose 
intolerance
134
, diabetes mellitus
135
, and obesity
136, 137
. Despite this impressive evidence linking 
vitamin D deficiency with CHD, the association between vitamin D deficiency and subclinical 
atherosclerosis, as measured by IMT and CAC, remains inconclusive.
92, 93
 IMT of the internal 
carotid but not of the common carotid had a significant association in 654 adults, aged 55-96.
91
 
CAC showed an inverse association with serum vitamin D levels in 173 adults
138
 but no 
association among 50 coronary angiography reported patients.
139
  
Despite consistent evidence on the associations between vitamin D deficiency and both 
CHD and its risk factors, for example high blood pressure, few studies on the association 
between subclinical atherosclerosis and vitamin D deficiency were examined. Further 
evaluations are needed among different populations. For example, Japanese men have very low 
49 
prevalence of atherosclerosis as compared to Caucasian men.
5
 To examine and explore the 
association between subclinical atherosclerosis and vitamin D deficiency among three different 
populations will extend our understanding of the relationship between vitamin D deficiency and 
CHD.  
The present study aimed to examine whether the vitamin D levels in Japanese men are 
higher due to habitual fish intake (major food source of vitamin D) than the levels in the other 
two study populations, Caucasian and Japanese-American men. Additionally, we examined 
whether vitamin D deficiency (defined as 25(OH)D<20ng/mL) is associated with subclinical 
atherosclerosis as measured by IMT and CAC. To test these hypotheses, a population-based 
cross-sectional study of 295 participants (99 Japanese, 98 Caucasian, and 98 Japanese-American 
men) from three study centers in the „Electron-Beam Tomography, Risk Factor Assessment 
among Japanese and U.S. Men in the Post-World War II Birth Cohort‟ (ERA-JUMP) study was 
examined.  
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3.3 METHODS   
3.3.1 Study population 
Detailed descriptions of the ERA-JUMP study population and measurements have been 
previously published.
5, 140
 Briefly, between 2002 and 2006, 926 men aged 40-49 years, were 
randomly selected from three study centers (313 Japanese men from Shiga, Japan, 310 Caucasian 
men from Pennsylvania, U.S., and 303 Japanese-Americans men from Honolulu, Hawaii). All 
participants were without cardiovascular or other severe diseases. For this vitamin D study, 300 
men, comprised of 100 men from each of the three study centers, were randomly chosen. After 
excluding five participants due to missing data, the final sample totaled 295 men (99 Japanese, 
98 Caucasians, and 98 Japanese-Americans). All participants signed informed consent forms. 
This study was approved by the Institutional Review Boards of the three institutions (Shiga 
University of Medical Science, Japan; the University of Pittsburgh, U.S.; and the Kuakini 
Medical Center, Honolulu).  
All participants, wearing light clothing and no shoes, took a physical examination to 
measure body weight and height. After empting their bladder and sitting quietly for five minutes, 
they had their blood pressure measurements taken twice and then averaged to use for analyses.  
Venipuncture was performed after the participants fasted for 12 hours. Blood samples 
were stored at -80C and then shipped on dry ice to the Heinz Laboratory, University of 
Pittsburgh, where using the standardized methods, fatty acids, insulin, and glucose were 
measured. The protocols standardized by the Centers for Disease Control and Prevention (CDC) 
51 
were utilized to measure serum lipids.
141
 Particularly, gas-capillary-liquid chromatography 
(PerkinElmer Clarus 500; PerkinElmer, Waltham, MA) was used to measure serum fatty acids in 
the percentage unit of total fatty acid amount.
6
 Marine n-3 fatty acids were defined as the sum of 
eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3), and 
docosahexaenoic acid (DHA, 22:6n-3). The intra-assay coefficients of variation (CV) were 2.5% 
for EPA, 2.5% DPA, and 7.0% DHA.
6
 C-reactive protein (C-RP) was measured by a 
colorimetric competitive enzyme-linked immunosorbent assay.
142
 
To gather information on the participants‟ demographic factors, alcohol and smoking 
habits, and medication usage, each participant completed a self-administered questionnaire. 
„Alcohol drinker‟ was defined as an individual who drank alcohol more than two days per week. 
„Current smoking‟ was referred to an individual who smoked cigarettes during the prior month. 
Hypertension was defined if a participant who had either a systolic blood pressure of ≥140 
mmHg or a diastolic blood pressure of ≥90 mmHg, or used anti-hypertensive medications. 
Diabetes mellitus was defined as a fasting serum glucose level ≥7 mmol/L (126 mg/dL) or 
medication usage for diabetes.  
3.3.2 Vitamin D measurement  
Serum 25(OH)D levels were measured with liquid chromatography-tandem mass spectrometry 
(LC-MS/MS), including both 25(OH) vitD2 and 25(OH) vitD3, at the Mayo medical 
laboratory.
143
 Circulating serum 25(OH)D, which can reflect total levels of vitamin D from both 
sun exposure as well as dietary intake, has been used to measure vitamin D levels in body.
88
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3.3.3 Intima-media thickness (IMT) 
The descriptions of detailed procedures to measure subclinical atherosclerosis were previously 
reported.
5, 144
 Trained sonographers used standardized procedures to measure IMT. They 
examined both far and near walls of thicknesses between lumen intima and media-adventitia, as 
well as the common carotid artery, which was 1cm proximal to the bifurcation. The scans were 
sent to read at the Ultrasound Research Laboratory, University of Pittsburgh. Measurements 
were averaged with each of the locations of right and left scorings. When trained readers 
performed scoring, they were blinded about the detailed information on the study subjects. The 
IMT scores have high reproducibility with high correlations (r=0.96) between sonographers and 
(r=0.99) between readers.
144
   
3.3.4 Electron beam computed tomography (EBCT)  
Scanning methods were standardized at each of three study centers by a GE-Imatron C150 
Electron Beam Tomography scanner (GE Medical Systems, South San Francisco, US). Scanned 
images were sent to the Cardiovascular Institute, University of Pittsburgh. One trained scan 
reader used a Digital-Imaging-and-Communications-in-Medicine (DICOM) workstation and 
software by Accu-Image (AccuImage Diagnostic Corporation, San Francisco, U.S.). The 
Agatston scoring method was used to calculate the coronary calcium score. The reproducibility 
of the Agatston calcium scores was 0.98 of the intraclass correlation.
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3.3.5 Statistical analyses 
To compare characteristics of risk factors among three population groups, an analysis of variance 
(ANOVA) test was used. Further, Bonferroni pair-wise comparisons were conducted for testing 
differences, which were considered significant at p<0.01. According to the literature review and 
the distribution of 25(OH)D within each study population, vitamin D deficiency was defined as 
less than 20 ng/mL of 25(OH)D.
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 To compare the vitamin D deficient and sufficient 
groups, a t-test and a chi-square test were utilized. For several variables with skewed 
distribution, a Kruskal-Wallis test for the three populations and a Mann-Whitney U test for the 
two group comparisons were utilized. To evaluate linear correlations between vitamin D 
deficiency and subclinical atherosclerosis measurements by IMT and CAC, correlation 
coefficients were examined. In order to assess the association between IMT and vitamin D 
deficiency, generalized linear models were utilized with log-transformed 25(OH)D levels. For 
the multivariate model, the following covariates were included: age (continuous), Body Mass 
Index (BMI) (continuous), hypertension (yes/no), diabetes (yes/no), alcohol (yes/no), current 
smoking (yes/no), LDLc (continuous), triglyceride (continuous), C-RP (continuous), and marine 
n-3 fatty acids (continuous). We had similar results with the categorical form of 25(OH)D on 
IMT in multivariate models. To examine the association between CAC and vitamin D 
deficiency, logistic regression models were tested. The CAC was defined as equal to or greater 
than 10 of a coronary calcium score. Additionally, no interactions were observed with several 
covariates, such as hypertension (yes/no), diabetes (yes/no), and obesity 
(obese/overweight/normal). All reported p-values were based on two-sided tests with the 
significance of less than 0.05.  All statistical analyses were performed using SAS 9.2 for 
Windows (SAS Institute, Inc., Cary, North Carolina, U.S.).  
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3.4 RESULTS 
3.4.1 Comparisons of risk factors among three study populations  
Table 16 shows the general characteristics of the study participants. The Japanese men were less 
obese, had a higher HDLc level, had a higher smoking, had a high alcohol consumption, and had 
more than twice the amount of marine n-3 fatty acids than the Caucasian men. The Japanese men 
had lower systolic blood pressure, triglycerides, hypertensive and diabetic rates, than the 
Japanese-American men, but higher LDLc levels.  
The serum vitamin D levels among the Japanese men were lower than the levels in the 
other two populations. Prevalence rates of vitamin D deficiency (defined as <20ng/ml) were 
43.4% (43 of 98) in Japanese men, 11.2% (11 of 98) in Caucasian men, and 9.2% (9 of 98) in 
Japanese-American men. Caucasian men appeared to have as much 25(OH)D as the Japanese-
American in Hawaii. The Japanese men also had lower IMT and CAC prevalence than the 
Caucasian and the Japanese-American men. The Japanese-American men had higher vitamin D 
levels than the other two populations. However, they also showed higher IMT levels and CAC 
percentages.  
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Table 16. Characteristics of the study participants during 2002-2006 (n=295) 
 
Caucasian 
(n=98) 
Japanese 
(n=99) 
Japanese-American  
(n=98) 
Age (year) 45.5 ± 2.8 45.0 ±2.9
 b
 46.4 ± 2.6 
BMI (kg/m
2
) 27.5 ± 4.5
a
 23.6 ±3.0
 b
 28.2 ± 4.2 
Systolic BP (mmHg) 122.7 ± 10.6 124.7±17.1 129.4 ±14.1
c
 
Diastolic BP (mmHg) 73.3 ± 8.1 75.2 ±11.7 78.9 ± 10.3
 c
 
Hypertension (n[%]) 13 (13.3) 22 (22.2)
 b
 41 (41.8)
 c
 
LDLc (mg/dL) 133.4 ± 34.4 134.1 ±34.4
b
 116.7 ±28.1
c
 
Triglycerides (mg/dL) §‡ 
119 
(92-163) 
132 
(96-176) 
163 
(96-286) 
HDLc (mg/dL) 47.7 ± 13.4
a
 53.4 ± 10.8 51.4 ± 13.9 
Total cholesterol (mg/dL) 207.8 ± 37.6 216.3 ± 39.5 206.9 ± 31.0 
Diabetes (n[%]) 3 (3.1) 6 (6.1) 17 (17.4)
 c
 
Current smoker (n[%]) 5 (5.1)
a
 55 (55.6)
 b
 16 (16.3) 
Alcohol drinker (n[%]) 42 (42.9)
a
 67 (67.7)
 b
 36 (36.7) 
n-3 fatty acids 4.5 ± 1.9
 a
 9.3 ± 3.1
 b
 4.7 ± 1.7 
Plant fatty acid  
(α-linolenic acid) 
0.2 ± 0.2 0.2 ± 0.1
 b
 0.4 ± 0.4
 c
 
Marine n-3 fatty acids 4.3 ± 1.9
 a
 9.1 ± 3.1
 b
 4.3 ± 1.7 
Serum vitamin D (25(OH)D) (ng/mL) 
(Mean, SD) 28.9 ± 8.5
 a
 20.8 ± 6.8
 b
 29.2 ± 8.0 
(Median, interquartile range) 
§‡  
28 (24-35) 21 (16-24) 28 (24-33) 
Carotid intima-media thickness (IMT) 
Common carotid IMT (mm) 0.64 ± 0.07 0.63 ± 0.08
 b
 0.71 ± 0.11
 c
 
Coronary artery calcification (CAC) 
Total calcium score §‡ 0 (0-8.2) 0 (0-1.8) 1 (0-37.4) 
Coronary artery calcification 
(CAC) (n[%]) 
22 (22.5) 13 (13.1)
 b
 31 (31.6) 
Mean ± SD; § Median (interquartile range); ‡ Kruskal-wallis for significance test, p<0.05; BMI=body mass index; 
LDLc=low density lipoprotein cholesterol; BP=blood pressure; HDLc=high density lipoprotein cholesterol; Marine 
n-3 fatty acids include eicosapentaenoic acid (20:5n-3), docosapentaenoic acid (22:5n-3), and docosahexaenoic acid 
(22:6n-3); n-3 fatty acids indicate the sum of α-linolenic acid (18:3n-3), eicosatetraenoic acid (20:4n-3), 
eicosapentaenoic acid (20:5n-3), docosapentaenoic acid (22:5n-3), and docosahexaenoic acid (22:6n-3); CAC is 
defined as those with coronary calcium score ≥10; 
Significance test was based on ANOVA followed by Bonferroni test if the overall ANOVA was significant.  
a. Under Bonferroni test, significant difference between Caucasian men and Japanese, p<0.01 
b. Under Bonferroni test, significant difference between Japanese and Japanese-American, p<0.01 
c. Under Bonferroni test, significant difference between Caucasian men and Japanese-American, p<0.01 
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3.4.2 Comparisons of risk factors between vitamin D deficient and sufficient groups 
according to three study populations  
Table 17 presents the comparisons among the vitamin D deficient and sufficient groups over the 
three populations. The Caucasian men in the deficient vitamin D group were elderly and had 
significantly higher systolic blood pressure levels than those men in the sufficient vitamin D 
group. No other significant differences were observed, but those men with vitamin D deficient 
levels tended to have higher levels of risk factors than those with vitamin D sufficient levels.   
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Table 17. Characteristics between vitamin D deficiency and sufficient groups (n=295) 
 
Caucasian  
(n=98) 
Japanese  
(n=99) 
Japanese-American  
(n=98) 
<20 ng/mL 
(n=11) 
≥20 ng/mL 
(n=87) 
<20 ng/mL 
(n=43) 
≥20 ng/mL 
(n=56) 
<20 ng/mL 
(n=9) 
≥20 ng/mL 
(n=89) 
Age (year) 47.3 ± 2.2* 45.3 ± 2.8 45.5 ± 2.9 44.6 ± 2.9 46.9 ± 3.1 46.3 ± 2.6 
BMI (kg/m
2
) 28.8 ± 4.2 27.3 ± 4.5 24.3 ± 3.2 23.1 ± 2.8 26.3 ± 5.0 28.4 ± 4.0 
Systolic BP (mmHg) 
129.3 ± 
12.8* 
121.9 ±10.1 125.8 ±16.4 123.9 ±17.7 131.6 ±13.6 129.2 ±14.2 
Diastolic BP (mmHg) 77.7 ± 8.3 72.7 ± 7.9 76.4 ±11.0 74.2 ±12.3 77.4 ± 7.7 79.1 ±10.5 
Hypertension (n[%]) 3 (27.3) 10 (11.5) 9 (20.9) 13 (23.2) 4 (44.4) 37 (41.6) 
LDL-C (mg/dL) 132.9 ±33.5 133.5 ±34.7 135.3 ±34.0 133.1 ±35.0 111.3 ±19.8 117.2 ±28.8 
Triglycerides  
(mg/dL) §‡ 
127  
(97-184) 
118  
(86-163) 
147  
(111-224) 
127  
(96-162) 
121 
(82-252) 
168  
(102-286) 
HDL-C (mg/dL) 46.2 ± 7.9 47.9 ±13.9 52.6 ±12.9 54.1 ± 9.0 54.9 ±19.0 51.0 ±13.4 
Total-C (mg/dL) 209.7 ± 29.9 207.6 ±38.6 218.9 ±37.5 214.2 ±41.2 202.0 ±18.3 207.4 ±32.1 
Diabetes (n[%]) 0 (0) 3 (3.5) 2 (4.7) 4 (7.1) 2 (22.2) 15 (16.9) 
Current smoker 
(n[%]) 
 1 (9.1)  4 (4.6) 24 (55.8) 31 (55.4) 1 (11.1) 15 (16.9) 
Alcohol drinker 
(n[%]) 
6 (54.6) 36 (41.4) 30 (69.8) 37 (66.1) 4 (44.4) 32 (36.0) 
n-3 fatty acids 4.6 ± 2.4 4.5 ± 1.9 9.6 ± 3.7 9.1 ± 2.6 4.5 ± 2.5 4.8 ± 1.6 
Plant fatty acid 
 (α-linolenic) 
0.1 ± 0.1 0.2 ± 0.2 0.2 ± 0.0 0.2 ± 0.1 0.4 ± 0.4 0.4 ± 0.4 
Marine n-3 fatty 
acids 
4.3 ± 2.4 4.5 ± 1.9 9.3 ± 3.6 8.9 ± 2.6 4.0 ± 2.5 4.3 ± 1.6 
Serum vitamin D (25(OH)D) (ng/mL) 
(Mean, SD) 14.1 ± 3.1* 30.8 ± 6.9 14.9 ± 3.2* 25.3 ± 5.2 17.0 ± 1.9* 30.5 ± 7.4 
(Median, 
interquartile-range)§‡  
15.0  
(12.0-16.0)*  
29.0  
(25.0-36.0)  
16.0  
(12.0-18.0)*  
24.0  
(21.0-27.5)  
17.0  
(17.0-18.0)*  
29.0 
(26.0-34.0) 
Carotid intima-media thickness (IMT) (mm) 
Common IMT  0.69± 0.07* 0.64 ± 0.07 0.63 ± 0.08 0.62 ± 0.09 0.68 ± 0.14 0.71 ± 0.11 
Coronary artery calcification (CAC) 
Total calcium 
score§‡ 
0  
(0-26.7) 
0  
(0-8.2) 
0  
(0-3.1) 
0  
(0-1.0) 
46.3  
(6.4-57.8) 
0  
(0-28.8) 
Coronary Calcium 
Score (n[%]) 
3 (27.3) 19 (21.8) 5 (11.6) 8 (14.3) 6 (66.7) 25 (28.1) 
Mean ± SD; § Median (interquartile range); * Under t-test or Mann-Whitney U test for a continuous variable and 
under chi-square test for a categorical variable between vitamin D deficiency and normal, p<0.05; S.E.=standard 
error; BMI=body mass index; LDL-C=low density lipoprotein cholesterol; BP=blood pressure; HDL-C=low density 
lipoprotein cholesterol; CAC is defined as those with coronary calcium score ≥10; Marine n-3 fatty acids include 
eicosapentaenoic acid (EPA, 20:5n-3), docosapentaenoic acid (DPA, 22:5n-3), and docosahexaenoic acid (DHA, 
22:6n-3); n-3 fatty acids indicate the sum of α-linolenic acid (18:3n-3), eicosatetraenoic acid (20:4n-3), 
eicosapentaenoic acid (20:5n-3), docosapentaenoic acid (22:5n-3), and docosahexaenoic acid (22:6n-3 
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3.4.3 Univariate and multivariate models to estimate risks on intima-media thickness 
associated with vitamin D deficiency 
Table 18 shows the univariate and multivariate associations of 25(OH)D levels on IMT. In a 
univariate model, 25(OH)D levels were a significantly and inversely associated with IMT only in 
Caucasian men (β=-0.23, p-value=0.022). However, in multivariate models adjusted for age, 
BMI, and other covariates (Models I, II, and III), the significant association between vitamin D 
deficiency and IMT disappeared. In Model III, marine n-3 fatty acid was included as a covariate, 
but the estimates and p-values rarely changed. Additionally, the present data did not show a 
significant correlation between 25(OH)D and marine n-3 fatty acids, even among the Japanese 
men (Pearson correlation coefficient [r]= -0.08, p-value=0.4624).  
 
Table 18. Univariate and multivariate regression models with intima-media thickness (IMT) 
(n=295) 
 
Caucasian 
(n=98) 
Japanese   
(n=99) 
Japanese-American   
(n=98) 
Model  S.E. p-value  S.E. p-value  S.E. p-value 
25(OH)D -0.23 0.022 0.022 -0.02 0.025 0.857 -0.07 0.042 0.497 
Model I -0.18 0.020 0.054 0.07 0.023 0.440 -0.08 0.040 0.422 
Model II -0.17  0.021     0.078 0.06       0.024    0.524 -0.09  0.041      0.388 
Model III -0.16 0.021 0.088 0.06 0.025 0.541 -0.09 0.042 0.401 
=Standardized parameter estimates; 25(OH)D was log-transformed; S.E.=standard error; Marine n-3 
fatty acids were defined as eicosapentaenoic acid (20:5n-3), docosapentaenoic acid (22:5n-3), and 
docosahexaenoic acid (22:6n-3). In univariate model, 25(OH)D was only adjusted; In model I, age and 
BMI were adjusted; In model II, hypertension, diabetes, current smoking, alcohol, LDL-cholesterol and 
triglyceride were further adjusted; In model III, c-reactive protein and marine fatty acids were 
additionally adjusted 
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3.4.4 Odds ratios on coronary artery calcification (CAC) associated with vitamin D 
deficiency   
Table 19 lists the associations between vitamin D deficiency and CAC. Unlikely the Japanese 
men and the Caucasian men, only the Japanese-American men showed significant associations of 
vitamin D deficiency on CAC. The Japanese-American men showed significantly increased odd 
ratios in an univariate model (OR=5.12, 1.19-22.07), even after adjusting for covariates 
(OR=8.02, 1.38-46.62).  
 
 
Table 19. Odds ratios on coronary artery calcification (CAC) associated with vitamin D 
deficiency  (n=295) 
 
Caucasian 
(n=98) 
Japanese   
(n=99) 
Japanese-American   
(n=98) 
Model OR 95% CI OR 95% CI OR 95% CI 
25(OH)D 1.34 0.32-5.56 0.79 0.24-2.61 5.12 1.19-22.07 
Model I 0.77 0.17-3.53 0.40 0.10-1.60 6.05 1.23-29.81 
Model II 0.92 0.19-4.37 0.42 0.10-1.78  8.02 1.38-46.62 
OR=Odds Ratio; Reference groups are 25(OH)D ≥20ng/mL; CAC is defined as those with coronary 
calcium score ≥10; CI=Confidence Interval; In univariate model, only vitamin D deficiency (defined as 
<20 ng/mL) was adjusted; In the model I, age and BMI were adjusted; In the model II, hypertension, 
alcohol, LDL-cholesterol and triglyceride were further adjusted 
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3.5 DISCUSSION 
In this population-based cross-sectional study, we found that the Japanese men do not have 
higher serum levels of vitamin D, despite their habitual fish intake which leads to high serum 
marine n-3 fatty acids, as compared to the Caucasian and Japanese-American men. We further 
found that vitamin D deficiency is not associated with subclinical atherosclerosis as measured by 
IMT and CAC, except for a few significant associations: 1) the Caucasian men had a significant 
inverse association of vitamin D on IMT only in a univariate model; and 2) the Japanese-
American men showed significant associations of vitamin D deficiency with CAC in both the 
univariate and multivariate models. 
Our findings of no association between vitamin D deficiency and subclinical 
atherosclerosis as measured by IMT or CAC are consistent with previous results. Michos and 
colleagues found no association with serum 25(OH)D levels on IMT of the common carotid 
artery (cIMT) and CAC in 650 Amish adults (cIMT ptrend=0.52, and CAC, ptrend=0.80).
92
 Pilz and 
colleagues demonstrated that serum 25(OH)D levels did not have a significant association with 
cIMT in 614 men and women (= -0.011, p=0.794).93 In a Women‟s Health Initiative (WHI), 
that a treatment group of receiving calcium plus vitaminD3 for seven years showed no difference 
on CAC, as compared to a placebo group (p=0.74).
149
  
In contrast, several studies are inconsistent with the present study. Targher et al. observed 
a strong inverse association on IMT associated with 25(OH)D among 390 type 2 diabetes 
patients (p<0.0001).
150
 A Multi-Ethnic Study of Atherosclerosis (MESA) by de Boer et al., 
which included 397 participants with chronic kidney disease and 976 without the disease, 
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showed that incident CAC (23% risk increase per 10 ng/mL of 25(OH)D decrease), but not 
prevalent CAC, was associated with low 25(OH)D for three years of follow-up.
97
 These 
inconsistent findings mostly shown in clinical patients with diabetes or chronic kidney disease.  
The lack of association between vitamin D deficiency and subclinical atherosclerosis may 
be attributable to the following potential confounding factors related to sunshine exposure: 
seasonal change, skin melatonin, physical activity, and job-related factors. Generally, dietary 
sources such as fish or fish oil (e.g. in salmon, tuna, mackerel), eggs, and fortified food products 
(e.g. milk, orange juice) contribute about 10-20% of the total vitamin D level; sunshine accounts 
for the remaining 80-90%.
88, 133, 148
 Latitudes of the Japanese study site (Kusatsu, Japan) and the 
U.S. study site (Pittsburgh, PA) are similar at 35°01'N and 40°26'N, respectively. Unexpectedly, 
the Japanese-American men, who live closer to the equator (Honolulu, Hawaii, 21°18'N) with 
year-round sunshine, showed higher subclinical atherosclerosis than the other two populations, 
and had a significant association with CAC but not with IMT.  
Availability to vitamin D fortified food products, as well as multi-vitamin 
supplementation practice in the Western culture, may explain the difference on serum vitamin D 
levels among the three populations. For instance, 14 (14.14%) Japanese men, 48 (48.98%) 
Caucasian men, and 61 (62.24%) Japanese-American men responded as “Yes, fairly regularly” 
to the question “Do you take vitamins regularly?” However, these numbers increased up to 37 
(37.37%) Japanese in Japan, 53 (54.08%) Caucasian, and 66 (67.34%) Japanese-American men, 
when occasional users who answered “Yes, but not regularly” were included. 
To take into account the different sources of vitamin D over three populations, we 
adjusted for marine n-3 fatty acids in the model. Additionally, we tested a possible link of marine 
n-3 fatty acids to 25(OH)D (correlation coefficients [r]= -0.3, p-value= <0.0001: specifically, in 
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the Japanese r= -0.1, p=0.46; in Caucasians r= -0.1, p=0.55; in Japanese-American r= 0.2, 
p=0.11), because fish is the primary food source of vitamin D, especially for the Japanese men.
90
 
We also tested and found that the three categories of 25(OH)D levels (<15, 15-30, ≥30ng/mL) 
had no association with IMT and CAC. The sample sizes for categories were too small for this 
examination. We further assessed whether IMT and CAC associated with vitamin D deficiency 
varied by hypertensive status or obese categories across three populations, but found that these 
variables did not modify the effects.  
A possible mechanism between vitamin D deficiency and CHD may be linked to blood 
pressure,
146
 not to subclinical atherosclerosis. Previous studies showed cross-sectional 
associations with blood pressure
94
 and hypertension
95
 in NHANES data, while prospective 
studies showed an increased risk on incident hypertension associated with 25(OH)D 
deficiency
100, 101
. In our data, systolic blood pressure was significantly associated with 25(OH)D 
deficiency in the Caucasian men (p-value =0.0283).  
Strengths include that the present study is a population-based sample, and the study 
questions were examined and explored in three different populations, including the Japanese men 
who have habitual fish intake, the Caucasian men who live in similar latitudes as the Japanese 
men and follow similar dietary and multivitamin supplement practices as the Japanese-American 
men, the Japanese-American men who live in Hawaii with year-round sunshine. However, this 
study has several limitations. The study participants were all men aged 40-49 years, which limits 
the generalizability to other populations (e.g. older or women). Second, the cross-sectional study 
design could not establish causality, which could limits the inference of study results. It may lead 
to reverse causality or residual confounding. Third, seasonality and physical activity 
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measurements were not available for this present study.  Fourth, the sample size was relatively 
small.  
In conclusion, vitamin D deficiency did not appear to be associated with subclinical 
atherosclerosis as measured by IMT and CAC. This finding may suggest an association between 
vitamin D levels and non-atherosclerotic cardiovascular disease risk, such as hypertension. 
Therefore, this present study provides a better understanding of vitamin D deficiency related to 
subclinical atherosclerosis. Future studies to examine causal relationships are warranted. 
 64 
3.6 REFERENCE 
1. O'Leary DH, Polak JF, Wolfson SK, Jr., et al. Use of sonography to evaluate carotid 
atherosclerosis in the elderly. The Cardiovascular Health Study. CHS Collaborative Research 
Group. Stroke 1991;22:1155-63. 
2. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness 
consensus (2004-2006). An update on behalf of the Advisory Board of the 3rd and 4th Watching 
the Risk Symposium, 13th and 15th European Stroke Conferences, Mannheim, Germany, 2004, 
and Brussels, Belgium, 2006. Cerebrovasc Dis 2007;23:75-80. 
3. Pletcher MJ, Tice JA, Pignone M, Browner WS. Using the coronary artery calcium score 
to predict coronary heart disease events: a systematic review and meta-analysis. Arch Intern Med 
2004;164:1285-92. 
4. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease 
incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in 
Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997;146:483-94. 
5. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK, Jr. Carotid-
artery intima and media thickness as a risk factor for myocardial infarction and stroke in older 
adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-
22. 
6. LaMonte MJ, FitzGerald SJ, Church TS, et al. Coronary artery calcium score and 
coronary heart disease events in a large cohort of asymptomatic men and women. Am J 
Epidemiol 2005;162:421-9. 
7. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status 
attenuates the age-associated increase in systolic blood pressure in white Americans: results from 
the third National Health and Nutrition Examination Survey. Am J Clin Nutr 2008;87:136-41. 
8. Kendrick J, Targher G, Smits G, Chonchol M. 25-Hydroxyvitamin D deficiency is 
independently associated with cardiovascular disease in the Third National Health and Nutrition 
Examination Survey. Atherosclerosis 2009;205:255-60. 
9. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum 
levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and 
Nutrition Examination Survey. Arch Intern Med 2007;167:1159-65. 
10. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of 
mortality in the general population. Arch Intern Med 2008;168:1629-37. 
11. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure 
in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007;20:713-9. 
12. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-hydroxyvitamin D levels and 
risk of incident hypertension. Hypertension 2007;49:1063-9. 
13. Forman JP, Curhan GC, Taylor EN. Plasma 25-hydroxyvitamin D levels and risk of 
incident hypertension among young women. Hypertension 2008;52:828-32. 
14. Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status and arterial hypertension: a 
systematic review. Nat Rev Cardiol 2009;6:621-30. 
 65 
15. Hypponen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British 
birth cohort: the role of obesity. Diabetes Care 2006;29:2244-6. 
16. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the 
Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2813-8. 
17. Arunabh S, Pollack S, Yeh J, Aloia JF. Body fat content and 25-hydroxyvitamin D levels 
in healthy women. J Clin Endocrinol Metab 2003;88:157-61. 
18. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the 
beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 
2009;89:1321-7. 
19. Michos ED, Streeten EA, Ryan KA, et al. Serum 25-hydroxyvitamin d levels are not 
associated with subclinical vascular disease or C-reactive protein in the old order amish. Calcif 
Tissue Int 2009;84:195-202. 
20. Pilz S, Henry RM, Snijder MB, et al. 25-hydroxyvitamin D is not associated with carotid 
intima-media thickness in older men and women. Calcif Tissue Int 2009;84:423-4. 
21. Reis JP, von Muhlen D, Michos ED, et al. Serum vitamin D, parathyroid hormone levels, 
and carotid atherosclerosis. Atherosclerosis 2009;207:585-90. 
22. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely 
correlated with coronary calcification. Circulation 1997;96:1755-60. 
23. Arad Y, Spadaro LA, Roth M, et al. Serum concentration of calcium, 1,25 vitamin D and 
parathyroid hormone are not correlated with coronary calcifications. An electron beam computed 
tomography study. Coron Artery Dis 1998;9:513-8. 
24. Sekikawa A, Ueshima H, Kadowaki T, et al. Less subclinical atherosclerosis in Japanese 
men in Japan than in White men in the United States in the post-World War II birth cohort. Am J 
Epidemiol 2007;165:617-24. 
25. Sekikawa A, Ueshima H, Sutton-Tyrrell K, et al. Intima-media thickness of the carotid 
artery and the distribution of lipoprotein subclasses in men aged 40 to 49 years between whites in 
the United States and the Japanese in Japan for the ERA JUMP study. Metabolism 2008;57:177-
82. 
26. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in 
healthy subjects: implications for reference intervals and epidemiological applications. Clin 
Chem 1997;43:52-8. 
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-
density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin 
Chem 1972;18:499-502. 
28. Sekikawa A, Curb JD, Ueshima H, et al. Marine-derived n-3 fatty acids and 
atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am 
Coll Cardiol 2008;52:417-24. 
29. Mayo Medical Laboratories. Serum 25-Hydroxyvitamin D2 and D3. (Accessed 
1/19/2010, at http://www.mayomedicallaboratories.com/test-catalog/Overview/83670.) 
30. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes 
FaNBIoM. Dietary Reference Intakes for Calcium, Phosphorous, Magnesium, Vitamin D and 
Fluoride; 1997. 
31. Thompson T, Sutton-Tyrrell K, Wildman R. Continuous Quality Assessment Programs 
Can Improve Carotid Duplex Scan Quality. Journal of Vascular Technology 2001;25:33-9. 
 66 
32. Sutton-Tyrrell K, Kuller LH, Edmundowicz D, et al. Usefulness of electron beam 
tomography to detect progression of coronary and aortic calcium in middle-aged women. Am J 
Cardiol 2001;87:560-4. 
33. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an 
important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 
2008;52:1949-56. 
34. Nemerovski CW, Dorsch MP, Simpson RU, Bone HG, Aaronson KD, Bleske BE. 
Vitamin D and cardiovascular disease. Pharmacotherapy 2009;29:691-708. 
35. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. 
36. Manson JE, Allison MA, Carr JJ, et al. Calcium/vitamin D supplementation and coronary 
artery calcification in the Women's Health Initiative. Menopause 2010;17:683-91. 
37. Targher G, Bertolini L, Padovani R, et al. Serum 25-hydroxyvitamin D3 concentrations 
and carotid artery intima-media thickness among type 2 diabetic patients. Clin Endocrinol (Oxf) 
2006;65:593-7. 
38. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS. 25-
hydroxyvitamin D levels inversely associate with risk for developing coronary artery 
calcification. J Am Soc Nephrol 2009;20:1805-12. 
39. Nakamura K, Nashimoto M, Okuda Y, Ota T, Yamamoto M. Fish as a major source of 
vitamin D in the Japanese diet. Nutrition 2002;18:415-6. 
 
 
 67 
4.0  MANUSCRIPT III: SERUM MARINE N-3 FATTY ACIDS ARE ASSOCIATED 
WITH CORONARY ARTERY CALCIFICATION (CAC) IN JAPANESE MEN IN 
JAPAN, BUT NOT IN CAUCASIAN MEN IN THE U.S.  
A manuscript in preparation for publication 
 
For the ERA-JUMP study investigators 
 
 
 
 68 
4.1 INTRODUCTION 
Coronary Heart Disease (CHD) mortality in Japan is much lower than that in Western countries. 
CHD mortality rates for men ages 35-74 in Japan (2004) and for men of the same ages in the 
U.S. (2005) were 50.4 and 169.4 (per 100,000 population), respectively.
10
 To study the 
determinants of the difference in CHD mortality between the Japanese men and men in the U.S. 
may help establish preventive methods. In order to decrease CHD mortality in the U.S., both 
early identification and primary prevention are important, since half of the men who had sudden 
death from CHD showed no previous symptoms.
4
 Coronary artery calcification (CAC), a non-
invasive and reliable measurement of subclinical atherosclerotic development, has shown strong 
associations with cardiovascular events.
29
 CAC also improves the CHD risk assessment over a 
traditional risk assessment (e.g. Framingham risk score), especially for individuals in the 
intermediate risk category.
32, 33
  
Among the participants of „Electron-Beam Tomography, Risk Factor Assessment among 
Japanese and U.S. Men in the Post-World War II Birth Cohort‟ (ERA-JUMP), Japanese men 
aged 40-49 years who adopted the Westernized lifestyle showed a similar or unfavorable profile 
with many traditional risk factors, as compared to the Caucasian men. Compared with the 
Caucasian men, the Japanese men in Japan had significantly higher rates of hypertension and 
cigarette smoking, similar levels of low-density lipoprotein cholesterol (LDLc), and similar 
prevalence of diabetes. In contrast, the Japanese men in Japan had significantly higher high-
density lipoprotein cholesterol (HDLc), significantly lower body mass index (BMI), and 
significantly lower C-reactive protein (CRP) than the Caucasian men. The ERA-JUMP study 
found that Japanese men in Japan have substantially lower prevalence rates of CAC, as 
 69 
compared to Caucasian men.
5
 The study also found that Japanese-American men have similar or 
higher subclinical atherosclerosis, as compared to Caucasian men.
6
 These data suggest that the 
environmental risk factors play a substantial role more than genetic factors in contributing to this 
substantially low prevalence rates of subclinical atherosclerosis and low CHD mortality of the 
Japanese men in Japan. This different CHD mortality is not attributable to misclassification of 
death code.
151
  
Our previously reported ERA-JUMP study found that: 1) the Japanese men in Japan aged 
40-49 showed more than twice the serum marine n-3 fatty acids than the Caucasian men of the 
same age, and 2) after adjusting for marine n-3 fatty acids, the significant difference in CAC 
prevalence between the two populations disappeared. These observations indicate that marine n-
3 fatty acids can explain the difference in subclinical atherosclerosis between the Japanese and 
the Caucasian men.
6
  
The extremely high levels of marine n-3 fatty acids in the Japanese men in Japan provide 
a unique opportunity to examine the following: 1) whether the incidence or progression of CAC 
is lower in the Japanese men in Japan than in the Caucasian men in the U.S. and 2) whether 
marine n-3 fatty acids are inversely associated with the incidence or progression of CAC. To 
achieve this, we tested the ERA-JUMP follow-up data of CAC scores associated with serum 
marine n-3 fatty acids in middle-aged men. Our study is the first one to examine the association 
between very high marine n-3 fatty acids and CAC changes in two populations: Japanese and 
Caucasian men. 
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4.2 METHODS     
4.2.1 Study population    
The ERA-JUMP study is a population-based multicenter study to measure prevalence and 
determinants of subclinical atherosclerosis in middle-aged men. Detailed descriptions of the 
study participants were previously published.
5
 All participants, ages 40-49 without clinical 
cardiovascular disease or cancer at enrollment, were randomly selected from three study centers 
between 2002 and 2006: 313 Japanese men from Kusatsu, Shiga, Japan; 310 Caucasian men 
from Allegheny County, Pennsylvania; and 303 Japanese-American men from Honolulu, 
Hawaii.  
For the ERA-JUMP follow-up study from 2007 to 2010, all participants from the 
previous examinations (from 2002 to 2006) were re-invited by mail or phone; the follow-up rates 
were about 83.7% (262 Japanese men) and 79.7% (247 Caucasian men) (this study did not focus 
on the Japanese-American men). After excluding missing data of coronary calcium scores (CCS) 
or one stent case, a total of 495 participants (253 Japanese and 242 Caucasian men) had both 
baseline and follow-up examinations. Because high alcohol consumption has a strong association 
with marine n-3 fatty acids and is a risk factor for CAC, the men who consumed more than 
69g/day of ethanol were excluded (23 Japanese men).
6, 152
 A total of 472 participants (230 
Japanese and 242 Caucasian men) were in the final analyses. All participants signed informed 
consent forms for both the baseline and the follow-up. Both the Institutional Review Boards of 
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the Shiga University of Medical Science, Japan, and the University of Pittsburgh, U.S., approved 
this study.  
4.2.2 Measurements of subclinical atherosclerosis risk factors 
Measurements at baseline from self-administered questionnaires were used to obtain information 
on demographic characteristics, drinking or smoking habits, and any medication usage. The 
detailed procedures were published elsewhere.
5
 Briefly, a physical examination to measure body 
weight and height was performed for all participants dressed in light clothing without shoes. 
After the participant emptied his bladder and sat quietly for 5 minutes, two measurements of 
blood pressure were averaged to use for analysis. „Alcohol drinking‟ was defined as consuming 
alcohol >2 days/week. Alcohol consumption (g/day) was calculated based on ethanol 
concentrations (e.g. 12% for wine, 16% for sake, 5% for beer, and 40% for liquor). „Current 
smoking‟ was defined as smoking over the last month.  
4.2.3 Serum fatty acids measurement 
Using gas-capillary-liquid chromatography (PerkinElmer Clarus 500; PerkinElmer, Waltham, 
MA), serum fatty acids were measured at baseline in the percentage unit of total fatty acid.
6
 The 
intra-assay coefficients of variation (CV) between runs were eicosapentaenoic acid (EPA, 20:5n-
3) 2.5%, docosapentaenoic acid (DPA, 22:5n-3) 2.5%, and docosahexaenoic acid (DHA, 22:6n-
3) 7.0%.
6
 Marine n-3 fatty acids were defined as the sum of eicosapentaenoic acid (EPA, 20:5n-
3), docosapentaenoic acid (DPA, 22:5n-3), and docosahexaenoic acid (DHA, 22:6n-3).  
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4.2.4 CAC measurement  
CAC was measured twice, both at the baseline (2002~2006) and at the follow-up (2007~2010), 
using either Electron Beam Computed Tomography (EBCT) or Multi-Detector Computed 
Tomography (MDCT). At baseline, both study sites used EBCT. As for the follow-up scans, the 
Japan site used MDCT, while the U.S. site used EBCT. 
EBCT and MDCT scanning were performed with a standardized study protocol in each 
of the two study sites. A GE-Imatron C150 Electron Beam Computed Tomography scanner 
(EBCT) (GE Medical Systems, South San Francisco, US), as well as MDCT scans using a 16 
multi-slice computed tomography (Toshiba Medical System Corporation, Tochigi, Japan), were 
utilized. At the Cardiovascular Institute in the University of Pittsburgh, a trained scan reader 
quantified CAC in the Agatston method, using a Digital-Imaging-and-Communications-in-
Medicine (DICOM) workstation and software by Accu-Image (AccuImage Diagnostic 
Corporation, San Francisco, U.S.).
153
   
4.2.5 Statistical analyses 
Using two scans both at baseline and follow-up, CAC prevalence, incidence, and progression 
were defined. The prevalence rate of CAC was defined as CCS≥10.6 The incidence of CAC was 
defined as participants with a CCS≥10 at follow-up among those with CCS=0 at baseline. The 
progression of CAC was defined as a higher CCS at follow-up than CCS at baseline among those 
participants with CCS>0 at baseline.  
To compare the general distributions of risk factors between the Japanese and the 
Caucasian men, a t-test for a continuous variable and a chi-square test for a categorical variable 
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were used. Because of a skewed distribution with such variables as triglycerides, ethanol, and 
CRP, a Mann-Whitney U test was used. The correlation coefficients between CAC and risk 
factors were evaluated. To assess the association between marine n-3 fatty acids and CAC 
incidence/progression, odds ratios were estimated using logistic regression models in univariate 
and multivariate models. Logistic models were adjusted as follows: adjustment for such 
covariates as age, follow-up time in year, smoking, and ethanol (model 1); further adjustment for 
hypertension and diabetes (model 2); additional adjustment for LDLc, HDLc, and triglycerides 
(model 3); and further adjustment for lipid medication and CRP (model 4).  The variable of 
„ethanol consumption (g/day)‟ was utilized as a categorical variable with „0, 1-15, 16-30, 31-45, 
46+‟. To confirm the results, Poisson regression models with robust (i.e. negative binomial 
distribution) were conducted to estimate the association between CAC (i.e. continuous form of 
coronary calcium scores) and marine n-3 fatty acids. All reported p values were based on the 
significance of less than 0.05 with two-sided tests. SAS 9.2 for Windows (SAS Institute, Inc., 
Cary, North Carolina, U.S.) was utilized for all statistical analyses. 
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4.3 RESULTS 
4.3.1 General characteristics 
Table 20 lists the general characteristics of the study population. The average ages of the two 
populations were both 45 years old. The Japanese men in Japan showed significantly higher rates 
of hypertension and cigarette smoking, as well as similar levels of LDLc and diabetes, as 
compared to the Caucasian men. In contrast, the Japanese men in Japan had significantly higher 
high-density lipoprotein cholesterol (HDLc), significantly lower body mass index (BMI), and 
significantly lower C-reactive protein (CRP), than the Caucasian men in the U.S. 
The Japanese men in Japan had significantly higher levels of serum marine n-3 fatty acids 
than the Caucasian men in the U.S. (p<0.0001) by 242.1%. 
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Table 20. General descriptions of the study population at baseline (n=472) 
 
Japanese men 
(n=230) 
Caucasian men 
(n=242) 
p-value 
Age (yrs) 45.1 ± 2.8 45.0 ± 2.9 0.93 
Body mass index (kg/m
2
) 23.7 ± 3.1 27.8 ± 4.0 <0.0001 
Systolic blood pressure (mm Hg) 124.7 ± 15.9 122.6 ± 10.9 0.09 
Diastolic blood pressure (mm Hg) 76.0 ± 11.6 73.3 ± 8.3 0.004 
Hypertension (%) 55 (23.9%) 34 (14.1%) 0.006 
LDL cholesterol (mg/dl) 134.2 ± 35.1 135.5 ± 31.8 0.67 
HDL cholesterol (mg/dl) 53.0 ± 13.2 47.1 ± 12.0 <0.0001 
Triglycerides (mg/dl)* 
139.0  
(105.0-181.0) 
130.0  
(95.0-186.0) 
0.27 
Current smoker (%) 109 (47.4%) 17 (7.0%) <0.0001 
Alcohol drinking (%) 149 (64.8%) 109 (45.0%) <0.0001 
Ethanol consumption (g/day)* 14.0 (2.0-36.0) 4.8 (0.9-16.1) <0.0001 
Diabetes mellitus (%) 12 (5.2%) 9 (3.7%) 0.43 
C-reactive protein (mg/l)* 0.3 (0.2-0.7) 1.0 (0.5-1.9) <0.0001 
Lipid-lowering medications (%) 6 (2.6%) 32 (13.2%) <0.0001 
Marine fatty acids  
[% of total fatty acids (mg/dl)] 
9.2 ± 2.8 3.8 ± 1.7 <0.0001 
*Median (interquartile range) with Mann-Whitney U test 
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4.3.2 Mean follow-up time 
Among those who had scans both at baseline and follow-up, the mean follow-up years were 6.17 
years (±0.33, median 6.26 years) in Japanese men in Japan and 4.64 years (±0.19, median 4.6 
years) in Caucasian men in the U.S.  
4.3.3 Prevalence of CAC  
Table 21 presents the prevalence of CAC between the two study populations. The Japanese men 
in Japan showed significantly lower prevalence rates (defined as ≥10) of CAC at both baseline as 
well as follow-up, than the Caucasian men (at baseline 8.7% vs. 26.0%, p-value <0.0001; at 
follow-up 17.0% vs. 38.4%, p-value <0.0001).  
 
Table 21. Prevalence of CAC among the study population (n=472)  
 
Japanese men 
(n=230) 
Caucasian men 
(n=242) 
baseline follow-up baseline follow-up 
Coronary artery calcification prevalence (%)  
(defined as CCS≥10) 20 (8.7%) 39 (17.0%) 63 (26.0%) 93 (38.4%) 
(defined as CCS>0) 65 (28.3%) 61 (26.5%) 130 (53.7%) 149 (61.6%) 
Coronary calcium 
score* [median  
(interquartile range)] 
0 (0-1.0) 0 (0-1.5) 1.2 (0-12.3) 3.0 (0-34.0) 
*Median with Mann-Whitney Test: <0.0001
 77 
4.3.4 Incident CAC and its risk factors 
Table 22 shows the distribution of risk factors between incident CAC and non-incident cases as 
well as incidence rates of the two populations. Among the Japanese men in Japan, those incident 
CAC cases had significantly higher rates of hypertension than non-incident CAC. No other risk 
factors were significantly different in either population. The incidence rate for the Japanese men 
in Japan was 1.0% (10 out of 165) for 6.2 years of follow-up, whereas that for the Caucasian 
men in the U.S. was 2.9% (15 out of 112) for 4.6 years of follow-up.  
 
 
 78 
 
Table 22. Comparisons of risk factors for incident CAC (n=277) 
 
Japanese men  (n=165) Caucasian men  (n=112)  
Incident 
(n=10) 
Negative 
(n=155) 
p-value 
Incident 
(n=15) 
Negative 
(n=97) 
p-value 
Age (yrs) 45.4 ± 3.6 44.8 ± 2.8 0.53 44.2 ± 2.9 44.7 ± 2.9 0.51 
Body mass index 
(kg/m
2
) 
22.8 ± 1.7 23.2 ± 2.9 0.67 27.7 ± 3.1 26.1 ± 3.0 0.07 
Systolic BP 
(mm Hg) 
140.6 ± 24.0 122.6 ± 14.2 0.04 122.7 ± 9.6 121.4 ± 11.3 0.67 
Diastolic BP 
(mm Hg) 
84.7 ± 16.2 74.2 ± 10.8 0.07 73.6 ± 8.4 71.5 ± 7.9 0.35 
Hypertension (%) 8 (80.0%) 26 (16.8%) <0.0001 2 (13.3%) 11 (11.3%) 0.69** 
LDLc (mg/dl) 120.8 ± 43.7 130.8 ± 35.6 0.40 125.7 ± 29.8 134.6 ± 31.5 0.31 
HDLc (mg/dl) 54.7 ± 13.5 53.9 ± 13.6 0.86 43.7 ± 7.7 48.7 ± 11.5 0.11 
Triglycerides (mg/dl)* 
129.5  
(120.0-143.0) 
131.0  
(96.0-174.0) 
0.86 
112.0 
(96.0-169.0) 
120.0 
(89.0-162.0) 
0.83 
Current Smoker (%) 6 (60.0%) 72 (46.5%) 0.41 0 (0%) 9 (9.3%) 0.61** 
Alcohol drinking (%) 8 (80.0%) 101 (65.2%) 0.34 8 (53.3%) 53 (54.6%) 0.92 
Ethanol consumption 
(g/day)* 
35.3  
(6.0-42.9) 
14.0  
(2.1-34.0) 
0.08 
6.2 
(0.8-27.8) 
8.2 
(1.6-17.3) 
0.99 
Diabetes (%) 1 (10.0%) 6 (3.9%) 0.36** 0 (0%) 2 (2.1%) >0.99** 
C-reactive protein  
(mg/l)* 
0.2 (0.3-0.6) 0.2 (0.3-0.6) 0.76 1.0 (0.7-1.8) 0.8 (0.4-1.6) 0.57 
Lipid medications (%) 0 (0%) 3 (1.9%) >0.99** 0 (0%) 9 (9.3%) 0.61** 
Marine fatty acids 
[% of total fatty acids 
(mg/dl)] 
8.5 ± 2.6 9.1 ± 2.5 0.46 3.5 ± 1.8 3.9 ± 1.8 0.38 
Calcium score at 
follow-up* 
27.9 
(13.9-70.2) 
0  
(0-0) 
<0.0001 
24.3  
(12.2-33.0) 
0  
(0-1.0) 
<0.0001 
Incidence 10/165 (6.1%) 15/112 (13.4%) 
Incidence rate 10/(165 * 6.2) (1.0%) 15/(112 * 4.6) (2.9%) 
Incidence is defined as coronary calcium score ≥10 at follow-up among those zero calcium score at 
baseline 
*Median (interquartile range) with Mann-Whitney Test;  **Fisher‟s Exact test 
BP, Blood Pressure; LDLc, LDL Cholesterol; HDLc, HDL cholesterol;
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Table 23 lists the associations of marine n-3 fatty acids with incident CAC. In the 
univariate model, both the Japanese men and the Caucasian men showed reduced risks for the 
incident CAC associated with marine n-3 fatty acids. In model I with the adjustment of follow-up 
year, smoking, and ethanol, both populations remained in reduced risk but not significant on the 
incident CAC associated with marine n-3 fatty acids. After adjusting for all covariates, including 
age, follow-up year, smoking, ethanol, hypertension, diabetes, LDLc, HDLc, triglycerides, lipid 
medication, and CRP, the Japanese men in Japan showed 54% (0.23-0.91) significant risk 
reduction on incident CAC associated with marine n-3 fatty acids. The Caucasian men had non-
significant 21% (0.5-1.22) risk reduction on incident CAC associated with marine n-3 fatty acids.   
 
 
Table 23. Associations of Marine n-3 fatty acids with Incidence Coronary Artery Calcification 
(CAC) in the Japanese men and Caucasian men (n=277) 
 
Japanese men 
(n=165) 
Caucasian men 
(n=112) 
OR (95% CI) OR (95% CI) 
Univariate 
(marine fatty acids) 
0.90 (0.69-1.17) 0.85 (0.59-1.22) 
Model I 0.76 (0.55-1.05) 0.80 (0.52-1.23) 
Model II 0.68 (0.46-1.01) 0.79 (0.51-1.23) 
Model III 0.56 (0.33-0.94) 0.78 (0.52-1.17) 
Model IV 0.46 (0.23-0.91) 0.79 (0.51-1.22) 
Univariate is adjusted for age; 
Model I is additionally adjusted for follow up year, smoking, and ethanol; 
Model II is further adjusted for hypertension and diabetes;  
Model III is further adjusted for LDLc, HDLc, Triglycerides;  
Model IV is additionally adjusted for lipid medication, and CRP.  
Incidence CAC was defined as coronary calcium score ≥10 at follow-up from zero CAC at 
baseline. 
Marine fatty acids are defined as the sum of the EPA, DHA, and DPA. 
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Table 24 shows that the Japanese men in Japan had significantly lower incident CAC 
than the Caucasian men (p=0.041) (n=277). As compared to the Japanese men, the significantly 
higher risk on the incidence of CAC in the Caucasian men remained in model I (with the 
adjustment of age, BMI, hypertension, and follow-up year), model II (with the further adjustment 
of LDLc, HDLc, triglycerides, ethanol, and lipid medication), and model III (with the additional 
adjustment of smoking, CRP, and diabetes). However, when further adjusting for marine n-3 
fatty acids, this significant difference on the incident CAC between the Japanese men in Japan 
and the Caucasian men was attenuated and became non-significant. 
 
 
Table 24. Differences in Incidence of Coronary Artery Calcification (CAC) between Japanese 
men and Caucasian men (n=277) 
 
Differences in the odds ratio  
between two groups  
OR (95% CI) 
p-value 
Univariate 
(race) 
2.40 (1.04-5.55) 0.041 
Model I 15.00 (1.12-201.86) 0.041 
Model II 18.22 (1.16-285.41) 0.039 
Model III 18.40 (1.11-305.59) 0.042 
Model IV 9.20 (0.50-168.81) 0.135 
Model I is adjusted for age, BMI, hypertension, and follow-up year;  
Model II is continuously adjusted for LDLc, HDLc, Triglycerides, ethanol, and lipid medication; 
Model III is further adjusted for smoking, CRP, and diabetes;  
Model IV is additionally adjusted for marine n-3 fatty acids.  
 
 81 
Table 25 and table 26 show associations with the continuous form of CCS. Table 25 
shows that the rate ratios of marine n-3 fatty acids on CCS at follow-up among those with zero 
CCS at baseline. In a univariate model (adjusted for age and ethanol), the Japanese men showed 
significant risk reduction (p=0.016), whereas the Caucasian men did not show significance 
(p=0.180). In the model I, II, and III, significant risk reduction on the increase in CCS associated 
with marine n-3 fatty acids were observed in the Japanese men in Japan, but not in the Caucasian 
men in the U.S. However, in model IV, after adjusting for lipid medication and CRP, the 
Caucasian men had significant risk reduction on the increase in CCS associated with marine n-3 
fatty acids.  
 
Table 25. Risks for the continuous changes of CAC among those zero CAC (n=277) 
 
Japanese men 
(n=165) 
Caucasian men 
(n=112) 
RR (95% CI) p-value RR (95% CI) p-value 
Univariate 
(marine fatty acids) 
0.62 (0.43-0.91) 0.016 0.75 (0.49-1.14) 0.180 
Model I 0.63 (0.45-0.88) 0.007 0.74 (0.49-1.12) 0.154 
Model II 0.65 (0.46-0.91) 0.011 0.73 (0.47-1.13) 0.153 
Model III 0.68 (0.47-0.99) 0.042 0.67 (0.44-1.02) 0.065 
Model IV 0.68 (0.46- 1.00) 0.049 0.65 (0.42-1.00) 0.049 
Univariate is adjusted for age and ethanol;  
Model I is continuously adjusted for smoking; 
Model II is further adjusted for hypertension and diabetes; 
Model III is additionally adjusted for LDLc and HDLc 
Model IV is further adjusted for lipid medication and CRP 
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The Table 26 shows that the Japanese men in Japan had significantly lower CCS than the 
Caucasian men (p=0.003). As compared to the Japanese men in the Japan, the Caucasian men 
had the significant increase in CCS in the univariate (with the adjustment of hypertension), 
model I (with the adjustment of age and BMI), model II (with the further adjustment of LDLc, 
HDLc, triglycerides, ethanol, and lipid medication), and model III (with the additional 
adjustment of smoking, CRP, and diabetes). However, when additionally adjusting for marine n-
3 fatty acids, this significant difference between the Japanese men in Japan and the Caucasian 
men disappeared. 
 
 
Table 26. Continuous differences in Coronary Artery Calcium scores between Japanese men and 
Caucasian men (n=277) 
 
Differences between two groups  
RR (95% CI) p-value 
Univariate 
(race) 
4.42 (1.69-11.56) 0.003 
Model I 4.37 (1.08-17.71) 0.039 
Model II 4.80 (1.05-22.06) 0.044 
Model III 5.86 (0.97-35.34) 0.054 
Model IV 1.18 (0.18-7.66) 0.863 
Univariate is adjusted for hypertension; 
Model I is adjusted for age, and BMI;  
Model II is continuously adjusted for LDLc, HDLc, Triglycerides, ethanol, and lipid medication; 
Model III is further adjusted for smoking, CRP, and diabetes;  
Model IV is additionally adjusted for marine n-3 fatty acids.  
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4.3.5 Progressive CAC and its risk factors 
Table 27 shows the distribution of risk factors between progressive CAC cases and non-
progressive cases. Those Japanese men who had progressive CAC had significantly higher levels 
of triglycerides than the Japanese men without progressive cases (p=0.005). The Japanese men in 
Japan showed no other significant risk factors. The Caucasian men who had progressive CAC 
used significantly higher rates of lipid medication than the Caucasian men without progressive 
CAC (p=0.03). The annual progressive rate of CAC for the Japanese in Japan was 4.5% (18 out 
of 65) for 6.2 years of follow-up, whereas that for the Caucasian men in the U.S. was 7.9% (47 
out of 130) for 4.6 years of follow-up.  
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Table 27. Comparisons of risk factors for progressive CAC (defined as advancement of CAC 
among those with CAC>0 at baseline) (n=195) 
 
Japanese men  (n=65) Caucasian men  (n=130) 
Progress 
(n=18) 
Negative 
(n=47) 
p-value 
Progress 
(n=47) 
Negative 
(n=83) 
p-value 
Age (yrs) 45.7 ± 2.5 45.5 ± 2.8 0.76 45.7 ± 2.7 45.2 ± 2.8 0.35 
Body mass index 
(kg/m
2
) 
25.8 ± 2.8 24.9 ± 3.5 0.36 29.0 ± 3.7 29.1 ± 4.7 0.92 
Systolic BP  
(mm Hg) 
127.6 ± 16.2 126.9 ± 17.1 0.88 123.6 ± 10.3 123.2 ± 11.2 0.82 
Diastolic BP  
(mm Hg) 
80.2 ± 10.7 78.8 ± 12.2 0.71 74.9 ± 8.1 74.4 ± 8.7 0.72 
Hypertension (%)  6 (33.3%) 15 (31.9%) 0.91 5 (10.6%) 16 (19.3%) 0.20 
LDLc (mg/dl) 149.5 ± 30.1 142.4 ± 30.7 0.40 135.6 ± 30.8 138.3 ± 33.1 0.64 
HDLc (mg/dl) 46.1 ± 11.9 52.1 ± 11.3 0.07 47.4 ± 13.0 45.6 ± 12.4 0.43 
Triglycerides 
(mg/dl)* 
215.0 
(146.0-246.0) 
140.0  
(118.0-182.0) 
0.005 
142.0 
(92.0-193.0) 
147.0 
(96.0-229.0) 
0.39 
Current smoker (%) 9 (50.0%) 22 (46.8%) 0.82 5 (10.6%) 3 (3.6%) 0.11 
Alcohol drinking (%) 11 (61.1%) 29 (61.7%) 0.97 20 (42.6%) 28 (33.7%) 0.32 
Ethanol (g/day)* 
7.0  
(1.6-40.5) 
11.4 
(1.5-37.0) 
0.96 
4.9 
(1.5-18.5) 
3.3 
(0-8.2) 
0.05 
Diabetes (%)  0 (0%) 5 (10.6%) 0.31** 2 (4.3%) 5 (6.0%) >0.99** 
C-reactive protein  
(mg/l)* 
0.4 
(0.2-0.9) 
0.3  
(0.2-0.7) 
0.29 
1.0 
(0.7-2.0) 
1.2  
(0.7-2.2) 
0.62 
Lipid medications 
(%) 
1 (5.6%) 2 (4.3%) >0.99** 13 (27.7%) 10 (12.1%) 0.03 
Marine fatty acids  
(%) 
10.1 ± 3.8 9.4 ± 3.3 0.49 3.7 ± 1.5 3.7 ± 1.7 0.97 
Coronary calcium 
score at baseline* 
 
at follow-up* 
 
8.2  
(3.9-37.8) 
 
68.6  
(47.0-126.5) 
4.1 
(1.3-11.3) 
 
0  
(0-9.5) 
0.05 
 
 
<0.0001 
25.3  
(5.5-68.4) 
 
125.0  
(47.7-266.7) 
6.1  
(2.4-18.9) 
 
5.5  
(0.0-33.6) 
0.0003 
 
 
<0.0001 
Progression 18/65 (27.7%) 47/130 (36.2%) 
Progression rate 18/(65 * 6.2) (4.5%) 47/(130 * 4.6) (7.9%) 
*Median (interquartile range) with Wilcoxon-Mann-Whitney Test 
** Fisher‟s Exact test 
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Table 28 lists associations of marine n-3 fatty acids with the progression of CAC 
(n=195). Marine n-3 fatty acids showed no significant associations in either population, even 
after adjusting for covariates.   
Table 29 shows the Japanese men in Japan had significantly lower progression of CAC 
than the Caucasian men (p=0.022) (n=195). As compared to the Japanese men, the Caucasian 
men had significantly higher progression of CAC. The significant differences on the progression 
of CAC were shown in univariate (with the adjustment of follow-up year), model I (with the 
further adjustment of age, BMI, hypertension, and ethanol), model II (with the additional 
adjustment of LDLc, HDLc, triglycerides, and lipid medication), and model III (with the further 
adjustment of smoking, CRP, and diabetes). However, when further adjusting for marine n-3 
fatty acids, this significant difference on the progression of CAC between the Japanese men in 
Japan and the Caucasian men was attenuated and became non-significant. 
 
Table 28. Associations of Marine n-3 fatty acids with the progressive CAC in both the Japanese 
men and the Caucasian men (n=195) 
 
Japanese men 
(n=65) 
Caucasian men 
(n=130) 
OR (95% CI) OR (95% CI) 
Univariate  
(marine fatty acids) 
1.05 (0.90-1.23) 1.00 (0.80-1.25) 
Model I 1.07 (0.89-1.29) 0.98 (0.77-1.25) 
Model II 1.06 (0.88-1.27) 0.98 (0.77-1.26) 
Model III 1.23 (0.98-1.54) 0.95 (0.73-1.25) 
Model IV 1.24 (0.97-1.57) 0.96 (0.73-1.27) 
Univariate is adjusted for age ; 
Model I is further adjusted for follow up year, smoking, and ethanol; 
Model II is continuously adjusted for hypertension, and diabetes;  
Model III is further adjusted for LDLc, HDLc, and Triglycerides;  
Model IV is additionally adjusted for lipid medication, and CRP.  
Marine fatty acids are defined as the sum of the EPA, DHA, and DPA. 
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Table 29. Differences in Progression of Coronary Artery Calcification (CAC) between Japanese 
men and Caucasian men (n=195) 
 
Differences in the odds ratio  
between two groups  
OR (95% CI) 
p-value 
Univariate 
(race) 
 15.41 (1.47-161.36) 0.022 
Model I  17.11 (1.49-196.13) 0.023 
Model II  17.20 (1.37-216.58) 0.028 
Model III 15.67 (1.18-207.65) 0.037 
Model IV  15.40 (1.06-222.84) 0.045 
Univariate is adjusted for follow-up year; 
Model I is adjusted for age, BMI, hypertension, and ethanol;  
Model II is continuously adjusted for LDLc, HDLc, Triglycerides, and lipid medication; 
Model III is further adjusted for smoking, CRP, and diabetes;  
Model IV is additionally adjusted for marine n-3 fatty acids.  
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Table 30 and table 31 show associations with the continuous form of CCS. Table 30 
shows that the rate ratios of marine n-3 fatty acids on CCS at follow-up among those with a 
prevalent CCS (>0) at baseline (n=195). In a univariate model as well as multivariate adjusted 
models (I, II, III, and IV), no significant associations of marine n-3 fatty acids on the progression 
of CAC were examined in the Japanese men in Japan and the Caucasian men.  
 
Table 30. Risks for the continuous changes of progressive CAC among those greater than zero 
CAC 
 
Japanese men 
(n=65) 
Caucasian men 
(n=130) 
RR (95% CI) p-value RR (95% CI) p-value 
Univariate 
(marine fatty acids) 
1.02 (0.87-1.20) 0.832 0.93 (0.79-1.09) 0.375 
Model I 1.02 (0.87-1.20) 0.782 0.93 (0.79-1.09) 0.376 
Model II 1.02 (0.87-1.19) 0.845 0.98 (0.84-1.16) 0.853 
Model III 1.07 (0.89-1.27) 0.482 0.98 (0.83-1.16) 0.845 
Model IV 1.07 (0.87- 1.31) 0.523 0.99 (0.85-1.16) 0.929 
Univariate is adjusted for age and ethanol;  
Model I is continuously adjusted for smoking; 
Model II is further adjusted for hypertension and diabetes; 
Model III is additionally adjusted for LDLc and HDLc 
Model IV is further adjusted for lipid medication and CRP 
Progressive CAC was defined as any advance of CAC among those with coronary calcium score 
>0 at baseline. 
Marine fatty acids are defined as the sum of the EPA, DHA, and DPA. 
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Table 31 lists that the difference of CCS at follow-up between the Japanese men in Japan 
and the Caucasian men among those with a prevalent CCS (>0) at baseline. The Japanese men in 
Japan had significantly lower CCS than the Caucasian men (p=0.014) in the univariate model 
(with the adjustment of hypertension). After adjusting for covariates, shown in model I (with the 
adjustment of age and BMI), model II (with the further adjustment of LDLc, HDLc, 
triglycerides, ethanol, and lipid medication), and model III (with the additional adjustment of 
smoking, CRP, and diabetes), the advancement of CCS were not significantly different between 
the Japanese men in Japan and the Caucasian men. When additionally adjusting for marine n-3 
fatty acids, this non-significant difference between the Japanese men in Japan and the Caucasian 
men remained. 
 
 
Table 31. Continuous differences in the progression of Coronary Artery Calcium scores between 
Japanese men and Caucasian men (n=195) 
 
Differences between two groups  
RR (95% CI) 
p-value 
Univariate 
(race) 
1.96 (1.15-3.34) 0.014 
Model I 1.64 (0.89-3.00) 0.110 
Model II 1.76 (0.87-3.53) 0.113 
Model III 1.82 (0.88-3.78) 0.108 
Model IV 1.78 (0.65-4.88) 0.266 
Univariate is adjusted for hypertension; 
Model I is adjusted for age, and BMI;  
Model II is continuously adjusted for LDLc, HDLc, Triglycerides, ethanol, and lipid medication; 
Model III is further adjusted for smoking, CRP, and diabetes;  
Model IV is additionally adjusted for marine n-3 fatty acids.  
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4.4 DISCUSSION 
In this follow-up study of 472 men ages 40-49, we found that the Japanese men in Japan had a 
significantly lower prevalence, incidence, and progression of CAC than the Caucasian men. In 
the multivariate-adjusted model, the Japanese men in Japan showed 54% significant risk 
reduction on incident CAC associated with marine n-3 fatty acids, whereas the Caucasian men 
had 21% non-significant risk reduction on incident CAC associated with marine n-3 fatty acids. 
The significant lower incident CAC in the Japanese men, as compared to the Caucasian men, 
was explained by marine n-3 fatty acids but not by traditional cardiovascular risk factors. The 
Japanese men and the Caucasian men did not show significant associations on the progression of 
CAC with marine n-3 fatty acids. The significantly lower progression rates of CAC in the 
Japanese men, as compared to the Caucasian men, was not explained either by traditional 
cardiovascular risk factors or by marine n-3 fatty acids.  
To the best of our knowledge, this present study is the first to examine the associations of 
very high marine n-3 fatty acids on the incidence or progression of CAC. Our findings of the 
beneficial effects of very high marine n-3 fatty acids on the incident CAC among those zero 
CAC at baseline suggested anti-atherogenic benefits. This beneficial effect is consistent with 
previous reports of two large Japanese studies that examined the associations between marine n-
3 fatty acids and significant risk reduction on non-fatal cardiovascular events.
54, 55
 These findings 
of the two studies with very high marine n-3 fatty acid for about 5 years of follow-up suggested 
anti-atherogenic effect. 
Additionally, the Rotterdam study of 1,570 asymptomatic participants with an average 
age of 64 found an inverse but weak association between higher fish intake (>19g/day) and CAC 
prevalence (mild to intermediate) as compared to those individuals with no fish intake 
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(significant prevalence rate (PR)=0.87, 0.78-0.98 for mild and intermediate calcification [CCS 
11-400], but non-significant PR=0.88, 0.74-1.04 for severe [>400]).
105
 However, EPA and DHA 
intake did not show significant associations (PR 0.93 and 0.97, p>0.05, respectively) on CAC, 
which the Rotterdam study defined as CCS>10.
105
 Also, the previous ERA-JUMP study that 
examined subclinical atherosclerotic burden associated with marine n-3 fatty acids demonstrated 
a significant difference in CAC prevalence (mean difference 10.7%, 2.9-18.4%) between the 
Japanese and Caucasian men, but no significant association between CAC (defined as ≥10) and 
marine n-3 fatty acids.
6
 In contrast, a large Multi-Ethnic Study Atherosclerosis (MESA) study 
did not demonstrate any significant association of dietary marine n-3 PUFA intake (220 vs. 40 
mg/d) with CAC (defined as >0) (1.14 [0.94-1.38]) among 6,814 participants ages 45-84 without 
clinical CVD.
106
  
Previous studies reported various risk factors for incident and progressive CAC. We 
found that hypertension in the Japanese men in Japan is a significant risk factor for incidence of 
CAC in middle-aged men without cardiovascular disease at enrollment. Japanese men showed 
higher rates of hypertension (23.9%) than Caucasian men (14.1%) at baseline. Another MESA 
study in patients with chronic kidney disease demonstrated such risk factors as male gender and 
diabetes.
43
 The observed significant risk factors for incident CAC included age, diabetes, and 
smoking, and for progressive CAC, diabetes, and smoking.
154
 A previously reported ERA-JUMP 
study showed a J-shaped association of alcohol consumption with CAC and a strong association 
in men with greater than 69g/day ethanol.
152
 Another study suggested pro-atherosclerotic relation 
to heavy alcohol consumers (>60g/day) via increasing platelet aggregation and promoting LDL 
oxidation.
155
 Especially, alcohol consumption is known to be positively associated with n-3 
polyunsaturated fatty acids, specifically those with CHD.
156
 Our present data also appeared to 
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have a positive association of alcohol consumption (i.e. ethanol amount) with marine n-3 fatty 
acids in the Japanese but not in Caucasian men, which the Japanese men have much higher 
amount of alcohol consumption than Caucasian men.  
Previous findings of the effectiveness of lipid-lowering treatments on the progressive 
CAC are inconsistent.
34-40
 Lipid oxidation and subsequent inflammatory responses has been 
considered to be attributable to developing atherosclerosis. Stains, lipid-lowering treatment, had 
drawn many attentions and expectation to show regressed progression of atherosclerosis. 
However, current findings on whether statins could effectively reduce CAC progression are 
inconclusive. Hecht et al. claimed that CAC is a predictor but not a prognostic factor.
157
 A meta-
analysis found that no effective reduction on CAC progression although statins reduced LDL 
cholesterol levels.
158
 Beckman and colleagues reported that those with acute coronary events had 
less calcium in stenoses than those with stable angina.
159
 These vulnerable plaques with less 
calcium may be more involved in inflammatory response with lipid oxidation, which makes 
more vulnerable to rupture.
159
 Since zero CAC does not mean zero risk of cardiovascular events, 
and CAC is known to be in the later stage of atherosclerosis,
160
 more future studies are 
warranted.  
Very lower CAC scores in the Japanese in Japan as compared to those of Caucasian men 
may be attributable to very high marine n-3 fatty acids. CAC presence and progression have been 
considered as a natural process of human aging. Min and his colleagues found that the mean 
duration of the CAC development was 4.1±0.9 years; the CAC occurrences, most prevalent in 
the fifth year, were in a skewed distribution.
154
 Within 5 years, a repeat scan is not recommended 
due to no detectable coronary calcium by EBCT scan.
161
 Our incident CAC data were measured 
at about and greater than 5 years of follow-up (6.2 years in the Japanese and 4.6 years in the 
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Caucasian men), indicating that those incident cases were valid. An annual CAC progression rate 
was reported as 25.1% for 4.1 years
154
.  
Possible underlying mechanism of beneficial marine n-3 fatty acids on incidence of CAC 
can be suggested that the beneficial effect of n-3 fatty acids on atherosclerosis may be 
attributable to stabilizing atherosclerotic plaques.
48
 Also, marine n-3 fatty acids has recently been 
suggested significant correlations with plaque stability and plaque inflammation.
162
 Previous 
studies showed the reduction of platelet-monocyte aggregation, suggesting anti-inflammatory 
effects of avoiding to form atheroma.
163
   
Strengths of the present study are followings: 1) we have firstly examined the association 
between very high marine n-3 fatty acid and incident/progressive CAC in a population-based 
cohort; and 2) the restricted age from 40 to 49 years allows to control possible confounding 
factors. However, this study also has several limitations: 1) The study population was men aged 
40-49 years in two study sites, which would limit the generalizability of the results to women 
and to other age groups. 2) MDCT measurements of the follow-up study in the Japanese data 
might have affected to lower CAC. However, the association of marine n-3 fatty acids with 
incident CAC was substantially stronger than that of the Caucasian men. A MESA study to 
examine dual scans between EBCT and MDCT showed very high concordance rates (96%, 
k=0.92).
164
 3) low CAC (1-10) was found to increase risk for mortality
165
, but it is not yet clear 
and future studies need to confirm whether incident CAC links to increase the CHD events.  
In conclusion, very high marine n-3 fatty acids are associated with reducing incident 
CAC. This present study may suggest anti-atherogenic effect of very high marine n-3 fatty acids. 
Future studies to examine the underlying mechanism of very high marine n-3 fatty acids on anti-
atherosclerosis are warranted.   
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5.0  DISCUSSION 
5.1 SUMMARY OF FINDINGS 
The major findings of three studies were: 1) in a population-based cross-sectional study of 915 
men aged 40-49, serum total n-6 fatty acids, including LA and AA, were inversely and 
significantly associated with plasma PAI-1, but not associated with plasma fibrinogen; 2) in a 
population-based cross-sectional sample of 295 middle-aged men, the Japanese men showed 
lower levels of serum vitamin D, despite high fish intake which is a major dietary source of 
vitamin D, than the Caucasian men or the Japanese-American men. In addition, vitamin D 
deficiency was not associated with subclinical atherosclerosis as measured by IMT and CAC, 
except for significant associations on IMT in an univariate model among the Caucasian men, as 
well as on CAC in both univariate and multivariate models among the Japanese-American men; 
and 3) in the ERA-JUMP follow-up study of 472 men, the Japanese men had a significantly 
lower prevalence, incidence, and progression of CAC than the Caucasian men. In the 
multivariate-adjusted model, the Japanese men showed 54% significant risk reduction on 
incident CAC associated with marine n-3 fatty acids, whereas the Caucasian men had 21% non-
significant risk reduction on incident CAC associated with marine n-3 fatty acids. The significant 
lower incident CAC in the Japanese men, as compared to the Caucasian men, was explained by 
marine n-3 fatty acids but not by traditional cardiovascular risk factors. On the other hand, the 
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Japanese men and the Caucasian men showed no significant associations on the progression of 
CAC with marine n-3 fatty acids. The significantly lower progression of CAC in the Japanese 
men, as compared to the Caucasian men, was not explained either by traditional cardiovascular 
risk factors or by marine n-3 fatty acids. These findings may contribute to extend our 
understanding on subclinical cardiovascular disease associated with n-3 and n-6 fatty acids as 
well as vitamin D. 
5.2 STRENGTHS AND LIMITATIONS 
The ERA-JUMP study has strengths as followings: 1) it has a population-based sample who were 
randomly selected from general population of three study centers; 2) three different study 
populations comprised of Japanese, Caucasian, and Japanese-American men allow us to compare 
environmental risk factors taken into account genetic differences; and 3) the study participants 
were restricted within men aged 40-49 years, which help avoid confounding factors.   
However, this study also has several limitations: 1) the first and second studies were conducted 
in a cross-sectional study, which could not assess a causal relationship; 2) the study population 
was all men aged 40-49, which may limit the generalizability into other populations such as 
women or other age groups; and 3) in the third study, CAC measurements among the Japanese 
men were examined in different CT technique between the baseline and the follow-up. However, 
the Japanese men showed substantially stronger association between marine n-3 fatty acids and 
CAC measurements than that of the Caucasian men. Also, a previous MESA study assessed the 
concordance rates of dual scans between EBCT and MDCT and showed very high concordance 
rates (96%, k=0.92).
164
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5.3 PUBLIC HEALTH SIGNIFICANCE AND FUTURE RESEARCH 
The present findings of three sub-topics have public health implications. The findings of the 
significant inverse association between serum total n-6 fatty acids and PAI-1 and the no 
association between serum n-6 fatty acids and fibrinogen suggest the beneficial effect of n-6 fatty 
acids on fibrinolytic response as one of cardioprotective benefits. We have firstly examined the 
associations of n-6 fatty acids on PAI-1 and fibrinogen. It is of public health important, because 
n-6 fatty acids are the main component of cooking vegetable oils, as well as PAI-1 and 
fibrinogen are independent predictors for CHD. A future study to examine the causality between 
n-6 fatty acid and PAI-1 as well as fibrinogen is warranted.   
Although many previous studies have demonstrated that vitamin D deficiency may 
increase CHD risk, few studies have examined the association between vitamin D deficiency and 
subclinical atherosclerosis over different populations. Because vitamin D is inexpensive, 
accessible, and safe, it is of public health importance if vitamin D could have a protective effect 
on subclinical atherosclerosis. Half of fatal events from CHD among men showed no previous 
symptoms.
4
 It is important to establish preventive guidelines as well as early identification. 
Future longitudinal prospective studies with larger sample size to examine causal relationships 
are warranted. 
The findings that high levels of serum marine n-3 fatty acids have a significant inverse 
association with the incidence of CAC, but not the progression of CAC, have an public health 
significance. The current findings suggest antiatherogenic effect of very high marine n-3 fatty 
acids. Future studies of a long-term clinical trial with high dose marine n-3 fatty acids on 
incident CAC in the U.S. general population are required.   
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